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1. Polycystic Kidney Disease, a common disorder needing effective
treatment
A. Clinical Aspects of the Disease
Polycystic Kidney Disease (PKD) is a genetic disease of the kidney with 4/10000 
prevalence1. PKD is characterized by the gradual replacement of normal kidney parenchyma 
by fluid-filled cysts and fibrotic tissue. Renal cysts grow and increase with age, leading to 
distortion of normal kidney architecture and ultimately, end-stage renal disease (ESRD) in a 
majority of patients. Clinical manifestations include a higher frequency of intracranial 
aneurysms (ICAs) and severe polycystic liver disease (PCLD), for which resection or other 
surgery may be required2. Other symptoms that PKD patients suffer from include, pain or 
tenderness in the abdomen, frequent urination, fatigue, kidney stones, and others. 
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is caused by mutations in the 
PKD1 or PKD2 gene and the less frequent autosomal recessive form, Autosomal Recessive 
Polycystic Kidney Disease (ARPKD), is caused by mutations in the PKHD1 gene1,3. PKD has 
a varying age of onset, where 50% of patients develop end-stage kidney disease by the age 
of 504.  
Diagnosis of ADPKD is mainly performed by renal imaging such as ultrasonography, 
computed tomography, or magnetic nuclear resonance5 and molecular diagnostics are 
necessary when a definite diagnosis is required. PKD’s molecular diagnostics are 
challenging, especially for ADPKD where the PKD1 gene is difficult to sequence. 
Approximately 70% of the 5′ genomic region of the PKD1 gene is duplicated six times on 
chromosome 16p within six pseudogenes (PKD1P1 to PKD1P6), which share a 97.7% 
sequence identity with the genuine gene6,7. The high GC content at the gene locus can also 
bias sequencing since more (or less) sequencing reads tend to come from a region with a 
higher GC content. Additional complications in sequencing the PKD1 gene arise from the 
presence of many missense variants, the absence of mutation hotspots, and the high allelic 
heterogeneity of ADPKD. As personalized medicine gains popularity, the demand for simple 
and cost-effective molecular approaches will increase. 
B. The role of Polycystins and the two-hit model in cyst formation
PKD1 and PKD2 protein products, Polycystin-1 (PC1) and Polycystin-2 (PC2). have been 
extensively studied, however their exact role in cyst formation is not yet fully understood. 
PC1 regulates signaling pathways essential for proper tubular structures in kidney and liver8-
12 and suggests that a threshold level might be required to prevent cyst formation13,14. 
Cystogenesis will begin when the level of functional PC1 is below the critical threshold15,16, 
and the degree at which the PC1 activity levels drop below this threshold determines speed 
of cyst formation and ADPKD severity.  A fundamental property of PC1 is its post-
translational modification by cleavage at the juxtamembrane GPS motif17, defective cleavage 
is thought to play a significant role in ADPKD’s pathogenesis. Additionally, PC1 C-terminal 
tail (PC1-CTT) has important signaling implications. Recently It was shown to regulate the 
complement factor B expression by signal transducer and activator of transcription 118. The 
PC1-CTT was also shown to associate with β-catenin and act as an inhibitor of Wnt-
dependent intracellular signaling, a signaling pathway that promotes epithelial cell 
9
General Introduction
proliferation and found upregulated in PKD patients19. However, the exact cellular functions 
of PC1 is yet to be fully understood. PC2 is a TRP-nonselective, Ca2+-permeable cation 
channel20 regulated by diverse stimuli including divalent cations, pH, voltage and 
phosphorylation20. PC1 has been hypothesized to form a mechanosensitive cation channel 
complex with PC2 in the primary cilia21-23. Functional defects in this complex caused by 
mutation of PKD1 or PKD2 result in autosomal dominant polycystic kidney disease 
(ADPKD)24,25. The cilium is a microtubule-based organelle found on most cells in the 
mammalian body. In the kidney, the primary cilia is present on most cells of the nephron and 
extend off the apical surface of the epithelium into the tubule lumen. It is now thought that 
the primary cilia senses fluid flow through the lumen of renal tubules by acting as a 
mechanosensor and initiating a cascade of downstream molecular signaling events. Altered 
signaling as a result of defective cilia function due to PKD1/PKD2 mutations is hypothesized 
to trigger cyst formation22,26. 
Despite this progress in understanding the functions of polycystins, the primary cause of cyst 
formation remains elusive. Understanding the main cause of cyst formation will enable 
targeting the primary rather than downstream secondary mechanisms which is likely to be 
more effective. Currently, the most widely accepted theory for cyst generation in human PKD 
is the “two-hit hypothesis.” ADPKD patients are typically heterozygous, with one PKD allele 
having a germline mutation (first hit) and the other is normal. The remaining normal 
PKD1/PKD2 allele develops a somatic mutation (second hit) in a small percentage of the 
cells. The “two-hit hypothesis” was demonstrated when the epithelial cells lining a human 
cyst were isolated and confirmed to be monoclonal, and found to have a loss of 
heterozygosity at the PKD1 locus (normal haplotype was lost)27. 
C. Targeting the Signaling Pathways Involved in PKD
There are many signaling pathways that appear to be compromised in PKD. These include 
activator protein-1 (AP-1) transcription factor, G-coupled protein receptors (GPCR), B-
Raf/ERK, mitogen-activated protein kinase (MAPK), EGFR signaling, mammalian target of 
rapamycin (mTOR), as well as second messengers like cAMP and Ca2+ (Figure-1). PC1 
directly binds the G-protein α-subunits and lead to the activation of subsequent signaling 
pathways such as AP-1 transcription factor, c-Jun N-kinase, and the nuclear factor of 
activated T-cell signaling cascade, which in turn regulate cell proliferation, differentiation and 
apoptosis28  (Figure-1). mTOR is a serine/threonine protein kinase that is involved in the 
regulation of cell proliferation, cell metabolism, protein synthesis and transcription. The 
polycystins, in part regulate the mTOR signaling pathway, as mTOR was shown to be 
increased in PKD29. In normal condition, PC1 inhibits mTOR signaling by stabilizing the 
TSC1/TSC2 complex, which is required for mTOR to function30. Interestingly, inhibitors of 
mTOR were shown to slow cyst formation at least in preclinical models of PKD31,32. Two 
large randomized clinical trials testing the mTOR inhibitors sirolimus and everolimus in 
ADPKD patients failed to slow the progression of the disease33,34. Cyclic AMP (cAMP), a 
second messenger involved in various cellular processes, including cell proliferation and 
differentiation, is elevated in human and animal model PKD35-37. By stimulating epithelial cell 
proliferation, cAMP is known to promote cyst development38,39. Strategies that focus on 
lowering cAMP levels have been successful in slowing cyst formation in animal and human 
PKD models. Somatostatin that works by inhibiting cAMP accumulation was shown to be 
effective in slowing progression in liver and kidney cystic disease in a rat model of PKD40. 
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The somatostatin analogue octreotide was also shown to be effective in reducing kidney 
volume in ADPKD patients41,42, and pravastatin is currently undergoing clinical trials for its 
effect on slowing cyst formation in young adults with ADPKD43. Additionally, the vasopressin 
V2 receptor antagonists tolvaptan that reduced renal cyclic AMP levels, inhibited renal 
cystogenesis and kidney enlargement44 and now is approved for therapy in Europe, Canada 
and Japan. Epidermal growth factor (EGF) plays an important role in cyst epithelial cell 
proliferation and cyst expansion. Inhibition of the epidermal growth factor receptor was 
successful in reducing cyst formation in a number of animal models of PKD45,46. Receptor 
tyrosine kinase inhibitors are also showing success in slowing the progression of PKD, in 
particular tesevatinib, is currently undergoing phase-2 clinical trials for ADPKD patients and 
had positive results in rodent models of autosomal recessive polycystic kidney disease47. 
Prominent defective metabolic rates have also been described in ADPKD animal models, 
providing additional opportunities for therapy. Modulation of the metabolic processes in PKD 
models either via diet-restriction or inhibition of glycolysis resulted in ameliorating the kidney 
volume, cystic index and reduced proliferation rates48-50. 
Figure-1: Overview of the signaling pathways affected by PC1 and PC2. PC1 and PC2 affect 
multiple signaling pathways. Figure-1 presents a summary of the signaling pathways 
influenced by PC1 and PC2. These pathways directly or indirect stimulate or inhibit different 
aspects of cellular growth and differentiation51.  
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D. Renal Injury aggravates PKD
Several studies indicated a tissue injury repair component in the pathology of PKD52-54. 
Indeed, there are numerous similarities between PKD and renal injury, since both 
phenotypes are accompanied by a combination of processes including proliferation, 
secretion of growth factors as well as inflammation. Weimbs proposed a model where 
Polycystin-1 (PC1), the protein encoded by PKD1, and primary cilia have a critical function in 
sensing renal injury, by detecting changes in luminal fluid flow, and triggering proliferation29. 
Besides a proposed mechanistic overlap, several studies showed that renal injury could 
stimulate cyst progression. For example, nephrotoxic injury in an ADPKD adult mouse model 
resulted in accelerated cyst formation and a more progressive phenotype52. This is further 
supported by findings that ischemic reperfusion injury and also tubular cell hypertrophy 
following unilateral nephrectomy accelerated PKD52,55,56. Although the link between PKD and 
renal injury seems rather strong, until now a thorough comparison between the two 
conditions at the molecular level has not been made, and little is known about the key genes 
and pathways shared between the two. 
2. Transcriptomics revolutionized the way we study diseases
A. Introduction of Transcriptomic Technologies
A transcriptome is the full range of RNA molecules expressed by an organism or a cell. This 
word appeared first in an article by Velculescu et al when they published the yeast 
transcriptome using Serial analysis of gene expression (SAGE) in 199757. The SAGE 
technology allowed for the cloning of short cDNA transcript fragments that are subsequently 
sequenced by Sanger sequencing and counted58. SAGE provided a comprehensive 
expression profiling for a given cell population unleashing the age of high-throughput 
expression profiling. The invention of the microarray technology in the mid 2000s allowed the 
assay of thousands of transcripts simultaneously at a greatly reduced cost per gene and 
labour savings59. Microarrays are a collection of microscopic DNA spots attached to a solid 
surface. The principle behind microarrays relies on the hybridization between two DNA 
strands. Complementary nucleic acid sequences pair forming hydrogen bonds. Microarrays 
use fluorescently labeled target sequences, which pass over the microarray probes and bind 
to complementary sequences generating a signal. The strength of this signal depends on the 
amount of target sample binding to the probes. Using relative quantitation, microarrays 
determine which probes are significant. The rapid development of high-throughput 
sequencing technologies gave rise to RNA-Seq. RNA-Seq refers to high-volume sequencing 
of cDNA transcripts. The key advantage of RNA-Seq over hybridization-based microarrays is 
the depth and novelty of the output based on unbiased sequence information60. The first 
application of RNA-Seq was published in 2006 with 105 transcripts sequenced61, now 
sequencing depth can exceed 109 62,63. This vast increase in yield makes it possible to 
accurately quantify the entire human transcriptome. It is now appreciated that 85% of the 
human genome can be transcribed and only 3% of it encodes protein-coding genes64. Thus, 
RNA-Seq has been instrumental to study the diversity of novel transcript species including 
long noncoding RNA, mircoRNAs, siRNA, and other small RNA classes (eg, snRNA and 
piRNA). These RNA species are gaining more importance in disease studies because of 
their involvement in regulating RNA stability, protein translation and modulation of chromatin 
states65. For instance, RNA-Seq has been used to discover enhancer RNAs, a class of short 
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transcript directly transcribed from the enhancer region, which contributes to our knowledge 
of epigenetic gene regulation66,67. In addition, RNA-Seq can give information about 
transcriptional start sites, revealing alternative promoter usage, information about alternative 
splicing, and transcription termination at the 3′ end, which is critical for mRNA stability68,69. 
RNA-Seq data essentially do not display background signal like microarrays, because 
transcripts that are not there will not be sequenced. However, background signal may arise, 
e.g. in pseudogenes, because ambiguous mapping of sequence reads in the genome (multi-
mapping). Since RNA-Seq is based on the number of sequences mapped there is no upper
limit to its quantification. In contrast, microarrays lack sensitivity for genes expressed at very
high or low levels. Continuous developments in the RNA-Seq technology allowed for pair-
end sequencing, strand-specific sequencing and single-cell sequencing.
Several limitations remain in the field of transcriptomics. The ideal method for 
transcriptomics should be able to directly identify and quantify all RNAs, small or large.  
However cDNA library construction is still required in RNA-Seq. This includes RNA 
fragmentation, reverse transcription, and PCR amplification. Each of these steps comes with 
biases that skew the representation of different RNA species in the sequencing data70. 
Another important aspect in transcriptomics is sequence coverage which correlates with 
increased costs. To detect rare transcripts and all possible isoforms in human samples, 
considerable sequencing depth (i.e.  >200 million paired-end reads) is required71. 
Additionally, data processing, storage, management and analysis are still a major bottleneck 
in transcriptomics. 
The transcriptomics field is expected to continue to develop and progress. The next big 
challenge for transcriptomics lies in data interpretation and the production of actionable 
insights in the upfront of medical and life sciences applications. Transcriptomics is not the 
only evolving omics technology. We are witnessing improvements in epigenetic profiling, 
proteomics and metabolomics as well. Each of the omics contributes a piece of information 
that is crucial for biomedical research. Proteomics complements transcriptomics by 
quantifying all proteins that are expressed, and modified following expression in a cell or a 
given tissue. Relying only on transcriptomics will miss the wide variety of chemical 
modifications i.e. phosphorylation and ubiquitination proteins undergo after translation. Many 
of these post-translational modifications are critical to the protein's function. Integrating 
transcriptomics with other omics is critical to our understanding of diseases and enabling the 
process of drug discovery. 
B. Applications of Transcriptomics
Transcriptomics has a wide range of applications across diverse areas of biomedical 
research. In disease diagnosis and profiling, RNA-Seq has allowed for the identification of 
transcriptional start sites at a large-scale and revealed novel alternative splicing events. 
Defining these variants is critical to the interpretation of disease association studies72 . 
Additionally, RNA-Seq is being used to study (allele-specific) gene expression regulation, 
identify disease-associated single nucleotide variants(SNVs) and somatic mutations, gene 
fusions, and RNA editing73-75. RNA-Seq is leading the way in expression profiling studies, 
where comparison of different disease states or of disease and control samples are 
becoming a commonplace in biomedical research. This has given rise to a wealth of 
information on molecular pathways and gene co-expression networks. For example the 
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application of gene co-expression network analysis, that identifies modules of genes 
expressed in a similar pattern, was applied to study the genes involved in several diseases, 
such as autism and cancer76,77. The identification of such modules and/or molecular 
pathways are changing drug discovery methods. Scientists are interested Identifying drugs 
that target key proteins of key expression modules and molecular pathways to discover 
novel drugs for a number of diseases78,79.  
C. Transcriptomics of Polycystic Kidney Disease
In renal diseases, transcriptomics was applied to study acute renal injury, chronic renal 
disease and polycystic kidney disease. Microarrays were the main platform used in the study 
of renal diseases. In these attempts, samples from patients and disease models were 
compared to wildtype controls and genes that were expressed differently were identified and 
further analyzed. In principle, the differentially expressed genes (DEGs) resulting from 
expression profiling experiments would reflect the genes involved in a certain disease and 
condition. However, DEGs can also arise as a result of differences in tissue, cellular 
composition and other experimental biases not related to the used expression capturing 
platform. In PKD, expression profiling experiments were attempted by several groups80-88. 
The depth and scope of these studies varied considerably. The biggest difference between 
the studies was the sample of origin used in the analysis. Studies varied from using cell 
lines, patient-derived material, and whole kidneys from rats or mice. Each type of sample 
provides a unique set of advantages and challenges. Human patient samples would seem 
ideal since they best reflect the disease under investigation. However, the disease is 
characterized by cysts arising from every nephron segment, so comparing “cystic” vs. 
“control” patient material could mean comparing different nephron segments, a fact rarely 
acknowledged or explicitly controlled for. Additionally, extracting the expression profiles from 
advanced stages of the disease may superimpose additional changes not related to the 
cause of cyst formation. Such changes can be the result of uremia and renal injury. 
Additional differences between the studies include sample size, technology used and 
downstream analysis of the resulting data. All of these factors have a large influence on the 
results obtained from the expression profile experiments. As one would expect from the 
many experimental differences between the different expression profiles performed on 
polycystic kidney disease, different conclusions were reached and a long list of pathways 
was suggested to be disease-related. Such pathways include extracellular matrix defects83, 
epithelial-to-myofibroblast transition85, apolipoprotein expression86, RXR pathways81, and 
various miscellaneous, broad functional categories involving signaling, metabolic and 
developmental pathways82,89,90. 
3. Data explosion and the need for proper integration
A. Historical and Projected Trends in Data Growth
With the advent of high-throughput omics technologies, life scientists are continuously 
generating large volumes of data (Figure-2). New technologies such as RNA-Seq, are 
making it easier and cheaper to perform experiments that generate large quantities of data 
(Figure-2). Genomics data are currently being produced at an unprecedented rate, doubling 
every seven months91. In fact, it is expected that data resulting from sequencing 
technologies only will reach more than exabase (10006) of sequence per year in the next five 
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years and approach one zettabase (10007) of sequence per year by 202591. This exponential 
growth in sequencing data is fueled by personalized medicine, large population sequencing 
projects, single cell genome sequencing projects and others. Additional sources of large 
data in biomedical research will come from other omic-technologies like proteomics and 
imaging.  
Figure-2: Number of sequences and bases deposited in the European Nucleotide Archive. 
The amount of sequences and DNA bases deposited in the European Nucleotide Archive – 
adopted from The European Nucleotide Archive in 2019. 
B. Challenges in Data Explosion
Life sciences is one of many other fields that have to deal with the emergence of big data. 
Other fields include, astronomics, education, banking and social media. According to IBM, 
big data are characterized by their volume, variety, velocity and veracity, also known as the 
four V’s of Big Data. The volume of data refers to the scale of big data. In life sciences, data 
is expected to grow exponentially reaching the magnitude of zettabytes in the near future. 
This dictates that storage capacity needs to be increased drastically to meet this vast 
increase in data. On the other hand improvements in data compression techniques and 
storage methods will become critical for data management. The properties of DNA sequence 
offer a chance to build DNA specific compression algorithms. One such technique is a 
reference-based compression method that efficiently compresses DNA sequences by 
comparing the genomic sequence to a reference genome and looking for differences92. 
Variety refers to the different forms of generated data, In life sciences data can come in 
many formats. In additions to omics, data in life sciences come in the form of text and tables 
in medical records and publications, multi-media from medical appliances and research 
related experiments and now data from social media of patient/doctor communities and 
personal medical devices. Each format of the aforementioned has its own challenges in 
terms of storage, processing and sharing. Data interoperability that relates to the ability of 
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systems and services to have clear expectations for the contents, context and meaning of 
the exchanged data, is a major challenge for the variety of data produced and consumed in 
life sciences. The velocity (speed of data generation) is at an ever increasing pace, now real-
time generated patient/doctor data is becoming a norm and immediate processing a must. 
The veracity refers to the certainty and the reliability of the data. As datasets continue to 
grow in size in life sciences, the presence of noisy data increases. This issue is of particular 
importance in medicine in which evidence-driven decisions are the foundation of patient 
care.  
To manage the requirements for the processing and storage of big data, solutions now apply 
the divide and conquer strategy. The idea is to partition a large problem into more tractable 
and independent subproblems93. Each subproblem is tackled in parallel by different 
processing units. In small scale, such divide-and-conquer paradigm can be implemented 
either by multi-core computing or grid computing. However the scalability of this solution is 
limited for the basic assumption, that at least one of the many different nodes is deemed to 
malfunction at one point. To solve this problem, big data algorithms copy the same data 
chunk to more than one node, making it available in case the other node failed [building in 
redundancy]. Cloud computing, defined as the practice of using a network of remote servers 
hosted on the Internet to store, manage, and process data, rather than a local server or a 
personal compute [Oxford Dictionaries:2017], are emerging as a feasible solutions for life 
sciences. Large cloud computing service providers such as Amazon are providing readily 
available infrastructure for the biotech and pharma industries. Data transfer speed remains a 
limiting factor despite the improvements in network infrastructure and more so in the less 
developed countries.  According to Akamai Q4 2015m the global average internet speed is 
5.6 Mb/s at which a 1GB file will take approximately 26 minutes to download. Other 
limitations to cloud computing include privacy concerns and copyright issues.   
C. Policies in Data Management
Data management is a critical aspect of maintaining a reliable data source, this is true for 
both large and small datasets. However, data management is gaining increased attention in 
the big data era. This is because incomplete data management policies that would work for 
small datasets are not feasible/applicable for large datasets. Data are considered as a 
valuable resource for industries and universities alike, and data loss or data silos are no 
longer accepted. There is an increasing need for data sharing to exploit most of the potential 
information lying within large datasets for added value and knowledge discovery. These 
rapid changes in how data is perceived are driving all data stakeholders to establish 
regulations and policies that direct how data should be stored, processed and shared.   
One such effort is seen in the The FAIR Data Principles, which are a set of guidelines put 
together by a team of stakeholders, representing academia, industry, funding agencies, and 
scholarly publishers, aimed at those wishing to enhance the reusability of their data 
holdings94. The four foundational principles of FAIR are, Findability, Accessibility, 
Interoperability, and Reusability. The FAIR Principles emphasize the ability of machines to 
automatically find and use the data.  Importantly, these principles must apply not only to 
‘data’ in the conventional sense, but also to the algorithms, tools, and workflows that led to 
that data94. In addition, data must be accompanied by a detailed and descriptive metadata 
section.The metadata is crucially needed to describe the data and how it was generated, as 
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well as putting it in context of other data sources. Data sources that adhere to the FAIR 
principles are easier to access, integrate and compare. Whilst, completely following the FAIR 
principles is challenging and can only be achieved gradually, databases can begin by adding 
metadata to their databases, modeling them into data structures that allow integration and 
querying. The Resource Description Framework (RDF), originally developed as a model to 
represent information about World Wide Web resources, is now commonly applied for the 
modeling of metadata and, to a lesser extent the data itself, in biomedical databases such as 
the EMBL-EBI Expression Atlas. RDF data can be queried using the SPARQL language 
[Prud, Eric, and Andy Seaborne. "SPARQL query language for RDF." (2006)]. Thus, the 
adoption of RDF across different biomedical databases is expected to facilitate the 
integration of life sciences data and allow scientists to devote more time on knowledge 
discovery. We are also witnessing the emergence of knowledge graphs in life sciences to 
integrate a large number of scattered databases. Knowledge graphs are networks of defined 
semantic concepts connected by edges based on a variety of resources. Edges can also be 
defined by semantically defined predicate types, that describe the type of the relationship 
connecting the two concepts. These graphs are read in the form subject-predicate-object 
and referred to as a semantic triple95. Examples of these efforts are the work of Hettne et al 
where they created a semantic knowledge graph of known drug disease associations, which 
was used to inference novel drug disease associations96 and the work of Chen et al where 
they built a semantic knowledge graph for drug targets associations by integrating data from 
public datasets relating to drugs, chemical compounds, protein targets, diseases, side 
effects and pathways97.  
The growth in scientific data is expected to continue growing at an exponential rate. 
Innovations in data storage, processing and sharing are critical to unleash the full potential of 
the generated data for scientific discovery. Additionally, there is a pressing need for scientific 
communities to get together and establish principles for data management. We are seeing 
an increased reliance on big data in life sciences and the study of human genetics combined 
with gradual shift in policy mandating better storage and sharing of datasets. Omic 
technologies will continue to take the center stage in the study of diseases, and consolidated 
databases will emerge. In PKD, we are witnessing accelerated drug discovery methods that 
rely on big data and high-throughput experiments. As is the case in other industries, data will 
be the most valuable asset in life sciences research and development.   
4. Aims and Outline of this Thesis
The aim of this thesis was to analyze Polycystic Kidney Disease (PKD) expression profiles to 
identify novel druggable gene targets and molecular pathways for its treatment.  
Noise attributed to intrinsic differences across different disease models is known to dilute the 
main disease signal and complicate the study of the disease characteristics. In chapter 2 we 
aimed at identifying a robust PKD Signature across different disease models and 
experimental setups. Using this signature, we aimed in chapter 3 at identifying key 
transcriptional factors that impact cyst formation. Transcription factors are known to 
orchestrate the expression of a large number of genes making them interesting drug targets. 
Since PKD is a progressive disease with varying molecular characteristics throughout its 
progression phases, in chapter 4, we aimed at identifying the key molecular pathways 
involved in each disease phase. We hypothesize that drugs targeting these key PKD genes 
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and molecular pathways will be important candidates for slowing down the cyst formation in 
PKD patients. 
In chapter 5 we evaluated drug discovery methods and in particular the possibilities of using 
semantic knowledge graphs for the discovery of novel drug disease associations and drug 
repurposing. Such graphs are interesting since they combine and integrate a large number 
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Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic renal disease, caused in the majority of
the cases by a mutation in either the PKD1 or the PKD2 gene. ADPKD is characterised by a progressive increase in the number
and size of cysts, together with fibrosis and distortion of the renal architecture, over the years. This is accompanied by alterations
in a complex network of signalling pathways. However, the underlying molecular mechanisms are not well characterised.
Previously, we defined the PKD Signature, a set of genes typically dysregulated in PKD across different disease models from
a meta-analysis of expression profiles. Given the importance of transcription factors (TFs) in modulating disease, we focused in
this paper on characterising TFs from the PKD Signature. Our results revealed that out of the 1515 genes in the PKD Signature,
92 were TFs with altered expression in PKD, and 32 of those were also implicated in tissue injury/repair mechanisms. Validating
the dysregulation of these TFs by qPCR in independent PKD and injury models largely confirmed these findings. STAT3 and
RUNX1 displayed the strongest activation in cystic kidneys, as demonstrated by chromatin immunoprecipitation (ChIP) follow-
ed by qPCR. Using immunohistochemistry, we showed a dramatic increase of expression after renal injury in mice and cystic
renal tissue of mice and humans. Our results suggest a role for STAT3 and RUNX1 and their downstream targets in the aetiology
of ADPKD and indicate that the meta-analysis approach is a viable strategy for new target discovery in PKD.
Key messages
& We identified a list of transcription factors (TFs) commonly dysregulated in ADPKD.
& Out of the 92 TFs identified in the PKD Signature, 35% are also involved in injury/repair processes.
& STAT3 and RUNX1 are the most significantly dysregulated TFs after injury and during PKD progression.
& STAT3 and RUNX1 activity is increased in cystic compared to non-cystic mouse kidneys.
& Increased expression of STAT3 and RUNX1 is observed in the nuclei of renal epithelial cells, also in human ADPKD
samples.
Keywords Autosomal dominant polycystic kidney disease . kidney injury . Gene expression . Transcription factors . Chromatin
immunoprecipitation
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Characterization of Transcription Factor Profiles in Polycystic Kidney Disease (PKD): 
Identification and Validation of STAT3 And RUNX1 in the Injury/Repair Response and PKD Progression 
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is a
genetic disease characterised by the formation of fluid-filled
renal cysts. Cyst formation and cyst growth are accompanied
by inflammation and fibrosis, leading to kidney failure. In the
majority of cases, ADPKD is caused by a mutation in the
PKD1 gene or, less frequently, in the PKD2 gene.
Nevertheless, ADPKD is a complex disease which involves
the dysregulation of many different signalling pathways [1],
and the molecular mechanisms involved in disease progres-
sion are not entirely understood. Currently, the vasopressin
V2-receptor antagonist, tolvaptan, is the only approved treat-
ment in Europe but only for selected patients. More generic
and definitive treatment is still missing.
Both environmental and genetic factors can be considered
disease modifiers in ADPKD [1, 2]. An important one is renal
injury, shown to accelerate cyst formation and expansion in
different mouse models [3, 4]. Recently, we showed that renal
injury shares molecular processes with ADPKD progression.
Using a meta-analysis approach, we identified a set of genes
dysregulated in a variety of PKD models during disease pro-
gression, which we called the “PKD Signature”. About 35%
of these genes were found to be also implicated in injury/
repair mechanisms, confirming the strong relation between
ADPKD and injury [5].
Transcription factor (TF) proteins are master regulators of
transcription, which control the expression of genes involved
in the establishment and maintenance of cell states, in physi-
ological and pathological situations. Dysregulation of TFs
levels and/or activity can lead to the development of a broad
range of diseases. Thus, identification of a TFs profile in
ADPKD could help to better understand the molecular mech-
anisms contributing to cyst formation. For this reason, in this
study, we focus on the signature of TFs. We identified new
PKD-related TFs, and we validated altered expression during
ADPKD progression and injury/repair in different mouse
models. For two of the identified TFs, STAT3 and RUNX1,
we also showed increased activity in mouse cystic kidneys, as
well as altered expression in human ADPKD kidneys.
Materials and methods
Identification of transcription factors in PKD
Identification of the PKD Signature was described previously
[5]. Briefly, in the previous work, we performed a meta-
analysis of PKD expression profiles across different disease
models and identified 1515 genes that showed consistent dys-
regulation across the different PKD studies. We further iden-
tified genes involved in injury/repair processes from the PKD
Signature by firstly producing injury repair gene profile based
on several injury-induced animal models and secondly
intersecting the identified PKD Signature and injury repair
profiles for the identification of overlapping genes.
In this publication, we used MSigDB’s collection of TFs
based on Messina et al. [6] and Moreland et al. [7] for the
identification of TFs involved in PKD. Furthermore, we iden-
tified the transcription factors that are involved in the injury/
repair processes of PKD based on the previously identified
injury repair profile [5].
The enrichment of TF targets in the PKD Signature was
based on the target collections in the ChEA 2016 database [8]
that includes TF targets based on experimental evidence. We
calculated the enrichment using the representation factor
method described below. TFs are considered enriched if they
had a representation factor above 1. The representation factor
is the number of overlapping genes divided by the expected
number of overlapping genes drawn from two independent
groups. A representation factor > 1 indicates more overlap
than expected of two independent groups, and a representation
factor < 1 indicates less overlap than expected. The formula
used to calculate the representation factor is x/(n × D)/N,
where x = # of genes in common between two groups; n = #
of genes in group 1 (the total number of targets calculated per
transcription factor based on ChEA 2016 database); D = # of
genes in group 2 (the total number of genes in the PKD
Signature up (775) or down (740) regulated lists independent-
ly); N = total genes, in this case, the 10,271 genes with Entrez
IDs.
In silico functional annotation of gene lists
GeneTrail2 v1.6 [9] was used to identify the enriched/
significant pathways/functions of the identified gene lists.
For all analyses, we usedWikipathways as the primary source
of annotation. GeneTrail2 v1.6 was run with the following
parameters: overrepresentation analysis (enrichment algo-
rithm); FDR adjustment (adjustment method); significance
level at 0.05; and minimum andmaximum size of the category
equal to 2 and 700, respectively.
Gene expression and statistical analysis
of the significance of results
Snap-frozen mouse kidneys were homogenised using MagNa
Lyser technology (Roche). Total RNAwas isolated using TRI
Reagent (Sigma-Aldrich). cDNA synthesis was performed
using Transcriptor First Strand cDNA Synthesis Kit
(Roche), and qPCR was done using 2× FastStart SYBR
Green Master (Roche) according to the manufacturer’s proto-
col. Alternatively, it was performed at GenomeScan
(GenomeScan B.V.) using the 96.96 BioMark™ Dynamic
Array for real-time PCR (Fluidigm Corporation), as previous-
ly described [5]. Gene expression was normalised to the
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geometric mean of three housekeeping genes (Rplp0,
Hnrnpa2b1, Ywhaz) for Fluidigm data and Hprt for SYBR-
Green data. The output of the Fluidigm assay was normalised
and converted into Ct values (cycle threshold). For each tran-
scription factor, a two-way ANOVA was conducted to com-
pare the genotype (PKD vs WT) and the treatment (PBS vs
DCVC) effects for each age-matched time points. The com-
putation was made using the Limma package [10] in R. A list
of primer sequences and TaqMan assays can be found in
Supplementary Table 3.
Identification of transcription factors binding sites
and primer design
For the TFs that were selected for our ChIP analysis, we iden-
tified the binding sites of each TF and its targets by screening
the Cistrome database [11] and accessing all studies that per-
formed ChIP-Seq experiments on our selected TFs. We
looked for peaks that appeared with an intensity of 10 or
higher in more than one ChIP-Seq study. We mapped the
Mus musculus mm10 genome to the peaks identified using
Peak2Gene tool that is part of the Cistrome Galaxy tools to
identify genes that are within 10,000 base pairs of both ends of
the peak. The peaks that did not map to a gene target that is
part of the PKD Signature were eliminated. Finally, sorting on
the intensity level of the peak, we visualised the top peaks on
the UCSC Genome Browser [12] and selected the peaks that
had sufficient height over noise levels for qPCR enrichment.
We designed primers spanning the TFs binding sites on their
putative target genes. The binding sites were generally over-
lapping with the promoter region of the target genes. As a
negative control, we designed primers binding at about 5 kb
from the promoter regions where we did not expect to find any
TF-binding activity. A list of primers can be found in
Supplementary Table 3. Two-way ANOVAwith Tukey’s mul-
tiple comparisons test was performed comparing the input-
normalised binding-enrichment of the TFs or the control IgG
at the binding site and at the nonbinding sites.
Animal model
All the animal experiments were evaluated and approved by
the local animal experimental committee of the Leiden
University Medical Center (LUMC) and the Commission
Biotechnology in Animals of the Dutch Ministry of
Agriculture. Kidney-specific tamoxifen-inducible Pkd1-dele-
tion mouse model (iKspPkd1del) have been described previ-
ously [13]. We only used male mice, to reduce variability in
disease progression as female mice tend to have a slower and
milder progression of the disease compared to male mice [14].
Wt mice have only the LoxP sites around exons 2–11 of the
Pkd1 gene but not the Cre recombinase (Pkd1loxlox). For three
consecutive days, 5 mg/kg of tamoxifen was administered via
oral gavage when mice were 13–14 weeks old. Inactivation of
the Pkd1 gene at this age leads to cyst formation in all the renal
tubule segments. Aweek later, mice were injected intraperito-
neally with 15 mg/kg of the nephrotoxic compound S-(1,2-
dichlorovinyl)-L-cysteine (DCVC) or vehicle (PBS) as a con-
trol. Kidney function was evaluated using blood urea nitrogen
(BUN) level as previously described [4]. Renal failure is de-
fined by BUN equal or higher than 25 mmol/l. Mice were
sacrificed at 1, 2, 5 and 10 weeks after DCVC and kidney
failure. The experimental pipeline has been presented in
Formica et al. [15]. The Wt + PBS, Wt + DCVC and Pkd1
KO + PBS groups have also been used in Malas et al. [5]. At
the sacrifice, kidneys were collected and weighed. For RNA
and chromatin extraction, kidneys were snap frozen in liquid
nitrogen. For immunohistochemistry (IHC) staining, kidneys
were preserved in phosphate-buffered 4% formaldehyde solu-
tion. A t-test was conducted to compare median survival in
PBS-treated versus DCVC-treated mice and BUN in Wt ver-
sus iKspPkd1del mice.
ChIP
Chromatin was isolated from mouse inner-medullary
collecting duct (mIMCD3; ATCC, Rockville, USA) cells
(about 5 × 106/ml). Briefly, cells were crosslinked with 1%
formaldehyde for 10 min at RT then lysed with buffer with
protease and phosphatase inhibitors (Roche) as described on
Nature protocols (ChIP buffer) [16].
For kidneys’ chromatin extraction, snap-frozen kidneys,
harvested at end-stage renal disease (ESRD) from Wt mice
and iKspPkd1del mice treated with DCVC or PBS, were cut
with a blade in a petri dish then fixed with 1% formalin (50
mg/ml) rocking for 12 min at RT. Glycine (0.125 M) was
added to stop the reaction, and the tissue was washed with
PBSwith serine protease inhibitor phenylmethylsulfonyl fluo-
ride (PMSF). The tissue was resuspended in cytoplasmic lysis
buffer and moved in a glass tissue grinder (Kimble Chase) for
homogenisation and then filtered using a 50 μm filter
(CellTrics® Sysmex). The homogenate was washed and then
lysed with ChIP buffer with protease and phosphatase inhib-
itors. Chromatin was sonicated in ChIP buffer using a
Diagenode Bioruptor® Pico (Diagenode) 30 s on/30 s off
for 15 cycles. Fragment size was checked by gel
electrophoresis.
For immunoprecipitation, 60 μg of chromatin were used
per reaction. Sepharose protein A alone or mixed 4:1 with
protein G (GEHealthcare) were used to preclear the chromatin
before incubation with primary antibodies for 4 h at 4 °C.
Primary antibodies used 5 μg rabbit anti-pSTAT3 (Cell
Signalling #9145); 8 μg mouse anti-RUNX1 (Santa Cruz
Biotechnology, Inc. #sc-365644); rabbit anti-IgG (Abcam
#ab37415) and mouse anti-IgG (Cell Signalling #5415S).
20 μl of Sepharose protein A (for pSTAT3) or A/G 4:1 (for
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RUNX1) were added to each sample and incubated overnight
at 4 °C. Samples were collected by centrifugation and washed
with low-salt wash buffer (150 mM NaCl, 20 mM Tris-HCl
pH 8.1, 2 mMEDTA, 0.1% SDS, 1% Triton X-100), high-salt
wash buffer (500 mM NaCl, 20 mM Tris-HCl pH 8.1, 2 mM
EDTA, 0.1% SDS, 1% Triton X-100), LiCl wash buffer
(10 mM Tris-HCl pH 8.1, 1 mM EDTA, 0.25 M LiCl, 1%
NP-40, 1% sodium deoxycholate) and twice with TE wash
buffer (10 mM Tris-HCl pH 8.1, 1 mM EDTA). Cross-links
were reversed incubating with Chelex®100 resin beads (Bio-
Rad #142-1253) at 99 °C for 15 min on a shaking block, and
then the samples were diluted 1:1 with MQ water.
IHC
Kidneys fixed in formalin and embedded in paraffin were cut
at 4 μm thickness. Sections were stained with the primary
antibodies used for ChIP: rabbit anti-pSTAT3 (1:75; Cell
Signalling #9145) and mouse anti-RUNX1 (1:250; Santa
Cruz Biotechnology, Inc. #sc-365644). Anti-rabbit or anti-
mouse Envision HRP (Dako) was used as the secondary
antibody.
Renal tissue from ADPKD patients at end-stage renal fail-
ure was fixed in formalin as previously described [15].
Control tissues were obtained from donor kidneys non-
suitable for transplant. All human tissue samples were collect-
ed following procedures approved by the LUMCmedical eth-
ical committee (institutional review board).
Results
Transcription factors in the PKD signature
Using a meta-analysis approach of published PKD expression
profiles and in-house generated RNA-sequencing data on our
Pkd1 mutant mouse model (iKspPkd1del), we recently identi-
fied 1515 genes that are commonly dysregulated across sev-
eral PKD disease models, hereafter referred to as the PKD
Signature [5].
We used MSigDB to identify the TFs that are part of the
PKD Signature (Fig 1a). Out of the 1515 genes of the PKD
Signature, we identified 92 TFs that were differentially
expressed and could be involved in cyst formation and PKD
development. Among the 92 TFs identified, 32 were also im-
plicated in tissue injury/repair mechanisms based on our pre-
viously defined injury repair profile (Supplementary Table 1)
[5]. Several of the herein identified TFs, such as STAT3 and
MYC, are known players in ADPKD progression [17, 18].
Nevertheless, many others have never been described in
ADPKD before.
Furthermore, we predicted TFs that are relevant to PKD
based on the enrichment of their targets in the PKD
Signature. Using the ChEA 2016 database of TF targets, we
identified TFs with more experimentally verified targets
(ChIP-chip or ChIP-Seq) overlapping with the PKD
Signature than would be expected by chance (Fig. 1a). The
TFs E2F7, TRIM28, TP63 (two different experiments in dif-
ferent cell lines), EGR1 and STAT3 were most significant in
this analysis (Supplementary Table 2a) since targets of these
TFs were mostly upregulated in PKD. Five TFs were both in
the list of TFs identified based on their targets and among the
92 TFs present in the PKD Signature: EGR1, ESR1, STAT3,
FOXM1 andKLF5. Thus, these TFs, as well as their identified
direct targets, were dysregulated in PKD (Supplementary
Table 2b). Further pathway analysis of these five TFs targets
uncovered involvement in the modulation of TGF-β signal-
ling, estrogen signalling, apoptosis, oxidative stress, interleu-
kins signalling, adipogenesis and cellular metabolism
(Supplementary Table 2c).
Validation of meta-analysis in independent samples
Our next step was to validate TFs identified in the meta-
analysis in independent experimental groups of mice during
PKD progression and/or the nephrotoxic injury/repair re-
sponse [15]. Briefly, we induced Pkd1 deletion in adult mice
via tamoxifen administration, which leads to a slow progres-
sion of the disease. Wild-type (Wt) mice received tamoxifen
as well. A week after tamoxifen administration, we injected
both genotypes with 15 mg/kg of DCVC, a nephrotoxic com-
pound or PBS as a control. At this dosage, DCVC causes a
repairable renal injury that is mostly recovered 1 to 2 weeks
after injection but accelerates cyst formation resulting in tubu-
lar dilations at 10 weeks and renal failure around 14 weeks of
age (Supplementary Fig. 1).Micewere sacrificed at 1, 2, 5 and
10 weeks after DCVC and at kidney failure. Kidneys harvest-
ed at these time points were used to evaluate gene expression
of selected TF using the Fluidigm qPCR chip (Fig. 1b). Out of
the 92 TFs, 13 were selected for further analysis, based on
transcript levels, altered expression in the injury/repair re-
sponse and involvement in multiple molecular pathways
(Supplementary Table 1). In our Fluidigm setup, we had four
groups: PBS-treated Wt, DCVC-treated Wt, PBS-treated
iKspPkd1del and DCVC-treated iKspPkd1del at five time
points (1week, 2weeks, 5weeks and 10weeks after DCVC
treatment and at kidney failure). Out of the 13 tested TFs, 11
were significantly different (P < 0.05) in PKD samples com-
pared toWt, while the involvement of Irf6 and JunB could not
be confirmed (Supplementary Table 1, Fig. 2). We also eval-
uated whether expression of the 13 TFs was affected by injury,
by comparing DCVC versus PBS-treated animals at injury-
related time points (1week, 2weeks and 5weeks after DCVC
treatment). Of the 13 selected TFs, 8 were part of the previ-
ously reported injury repair profile, while 5 were not [5]. We
confirmed significant injury-induced dysregulation (P < 0.05)
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of 6 out of 8 TFs predicted to be involved in the injury/repair
mechanism by the meta-analysis, while we did not see any
significant dysregulation of the expression of 3 out of 5 TFs
that were not found in the meta-analysis (Supplementary
Table 1, Fig. 2) [5]. Notably, the expression of Runx1 and
Stat3 was most significantly affected by DCVC-induced inju-
ry and PKD progression.
Expression of two selected TFs in mouse kidneys
during ADPKD progression and after injury
To further support the utility of meta-analysis approaches to
new target discovery in ADPKD, we chose STAT3 and
RUNX1 for additional experimental validation.
We performed immunohistochemical analysis for the
active form of STAT3 (pSTAT3) and RUNX1 and stud-
ied activation and subcellular localisation. In non-
injured Wt and iKspPkd1del mice, pSTAT3 and
RUNX1 are not detectable, except for some interstitial
cells that show nuclear staining. Interestingly, after inju-
ry (at 1wk after DCVC), there was an intense nuclear
expression of pSTAT3 and RUNX1 in both Wt and
iKspPkd1del mice (Fig. 3a and Supplementary Fig. 2a).
At 10 weeks post-DCVC, Wt mice have fully healed
the renal damage and have largely pSTAT3 and RUNX1
negative kidneys, comparable to the Wt treated with
PBS. Conversely, iKspPkd1del mice, which already de-
veloped some mild cysts at this time point, showed
expression of pSTAT3 and RUNX1 in the cyst-lining
epithelial cells and some of the surrounding dilated tu-
bules (Fig. 3b, middle panel and Supplementary Fig. 2b,
middle panel). iKspPkd1del mice treated with PBS, in-
stead, have not undergone injury/repair phase nor
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Fig. 1 Schematic representation of the workflow used for the
identification and validation of TFs involved in PKD and injury/repair.
aMSigDB was used to select the TFs in the PKD Signature. ChEA 2016
was used to select the TFs with most deregulated, experimentally verified
targets in the PKD Signature (note: the ChIP-chip and ChIP-Seq experi-
ments in ChEA 2016 were typically from cell lines not necessarily related
to the kidney). The TFs identified with MSigDB in the PKD Signature
were intersected with the injury signature generated in our previous work
[5] to obtain TFs involved in injury/repair mechanism, and TFs involved
only in PKD progression. Fluidigm assay was used to validate the
expression of selected TFs identified by this analysis. The TFs identified
based on their target genes using the ChEA 2016 database were
intersected with the TFs identified in the PKD signature to identify the
overlapping TFs. In silico pathway analysis was performed on the over-
lapping TFs and their target genes to identify significant pathways mod-
ulated by the TFs. b Schematic representation of the workflow used to
identify and validate selected TFs. The two most significant TFs identi-
fied were STAT3 and RUNX1 which were further investigated in cystic
kidneys using chromatin immunoprecipitation-qPCR (ChIP-qPCR) and
immunohistochemistry (IHC)
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showed almost no expression of pSTAT3 and RUNX1,
as expected.
At kidney failure, iKspPkd1del mice present severe renal
degeneration and cyst formation. At this time point, the ex-
pression of pSTAT3 and RUNX1 is markedly increased (Fig.
3b, right panel and Supplementary Fig. 2b, right panel).
Interestingly, not only epithelial cells but also infiltrating cells
stained positive for these TFs, suggesting that pSTAT3 and
RUNX1 might be important in the regulation of signalling
pathways in other cell types in addition to tubular epithelial
cells (Fig. 3b, arrowheads).
In summary, we confirmed that pSTAT3 and RUNX1 pro-
tein expression were increased in the nuclei of tubular epithe-
lial cells after injury and during PKD progression.
Fig. 2 Expression of selected TFs using Fluidigm assay. TFs selected
from the PKD Signature for experimental validation were subjected to
qRT-PCR on RNA isolated from the kidneys of iKspPkd1del mice and
age-matched Wt mice at 1, 2, 5 and 10 weeks after DCVC and at kidney
failure. On the Y-axis, normalized Ct values (cycle threshold values) are
plotted for each gene separately across the five measurement time points
for four types of samples: Wt mice treated with saline (Wt PBS, salmon),
iKspPkd1del mice treated with saline (iKspPkd1del PBS, light green), Wt
mice treated with DCVC (Wt DCVC, light blue) and iKspPkd1del mice
treated with DCVC (iKspPkd1del DCVC, light purple). The analysis was
based on comparing treatment (DCVC vs PBS) and genotype
(iKspPkd1del vs Wt) using a two-way ANOVA test. The resulting P
values are shown with colour codes: darkest colour shade, P value <
0.0005; medium colour shade, P value < 0.005 and low colour shade at
P value < 0.05. P value ≥ 0.05were not considered significant (grey bars).
Each dot is a mouse and whiskers reflect the mean ± SD. Expression of
Glis2 and Stat3 in Wt PBS, iKspPkd1del PBS and Wt DCVC have been
published in Malas et al.(2017) [5].
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Stat3 and Runx1 target genes were dysregulated
during ADPKD progression and after injury
Although we demonstrated that pSTAT3 and RUNX1 expres-
sion were increased during ADPKD progression and after
injury, both at gene and protein level, we do not know if this
would translate into differences in their activity as transcrip-
tional regulators. Thus, we quantified the expression of their
target genes during PKD progression and injury/repair. To
find TFs’ target genes, we used the publicly available
Cistrome database. For both TFs, we identified ChIP-Seq ex-
periments and searched for peaks (targets) identified in at least
two ChIP-Seq experiments. Peaks were prioritised based on
(1) the number of studies theywere found in, (2) their intensity
levels (> 10) and (3) whether they mapped to target genes
within 10 kb distance. For both TFs, the top putative target
genes were crossed with the PKD Signature genes to identify
targets that show differential expression in PKD. Only target
Fig. 3 Expression of pSTAT3 and RUNX1 in Wt and iKspPkd1del mice
after injury and during cyst progression. a Representative
immunohistochemistry of Wt and iKspPkd1del kidneys at 1 week after
DCVC (+ injury) or PBS (– injury). Mice without injury showed only
sporadic expression of pSTAT3 in the nuclei of tubular epithelial cells
(asterisks); after injury, the expression wasmarkedly increased both inWt
mice and in iKspPkd1del mice. RUNX1 expression in non-injured kidney
was present only in some interstitial cells (arrowheads); after injury,
RUNX1 was visible in the nuclei of the epithelial cells. b
Representative immunohistochemistry of Wt and iKspPkd1del kidneys
at 10 weeks after DCVC (“10weeks”; left and middle panel) showed
expression of pSTAT3 and RUNX1 in nuclei in cyst-lining epithelia, in
the epithelial cells of surrounding dilated tubules (arrows) and in infiltrat-
ing cells (arrowheads) only in cystic tissue. Expression of pSTAT3 and
RUNX1 was even more increased at kidney failure (“KF”; right panel)
when the kidneys are severely cystic. Scale bars 50 μm
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genes that were also present in the PKD Signature were se-
lected for further analysis (Fig. 4a).
The final targets we selected are Scp2, Kif22, Stat3
(autoregulation) and Socs3 for STAT3 and Runx1 (autoregu-
lation), Tnfrsf12a and Bcl3 as targets for RUNX1.We checked
the expression of these targets after injury and during PKD
progression in iKspPkd1del and Wt mice. We found that, in
iKspPkd1del mice, all targets were significantly upregulated
except for Scp2, which was downregulated, suggesting an
inhibitory effect of STAT3 on Scp2 transcription (Fig 2b,
Stat3 and Runx1; Fig. 4b, Scp2, Kif22, Socs3, Tnfrsf12a and
Bcl3).
These data indicate that not only the level of expression of
the selected TFs is dysregulated during injury/repair and PKD
progression but likely also their activity, as denoted by the
dysregulated expression of their target genes.
Stat3 and Runx1 ChIP-qPCR in murine renal epithelial
cells
To confirm that STAT3 and RUNX1 are directly regulating the
expression of the indicated target genes in the renal epitheli-
um, we performed chromatin immunoprecipitation (ChIP)
analysis followed by quantitative PCR (ChIP-qPCR). We first



























Fig. 4 Identification of STAT3
and RUNX1 target genes. a
STAT3 and RUNX1 emerged as
two leading candidates for wet-
lab validation. Using Cistrome
database, we identified ChIP-
peaks that were used in the wet-
lab validation process and led to
the identification of confirmed
STAT3 and RUNX1 targets. b
Expression of STAT3 and
RUNX1 targets during PKD pro-
gression. Total RNAwas isolated
from kidneys of Wt and
iKspPkd1del mice treated with
PBS or DCVC at 1, 2, 5 and 10
weeks and at kidney failure.
Expression of selected STAT3
(Scp2, Kif22 and Socs3) and
RUNX1 (Bcl3, Tnfrsf12a) targets
was evaluated using a SYBR
Green-based qPCR. On the Y-ax-
is, normalised Ct values (cycle
threshold values) are plotted. Data
were analysed using a two-way
ANOVA test based on comparing
treatment (DCVC vs PBS) and
genotype (iKspPkd1del vs Wt). P
values are reported and classified
into high significance (darkest
colour shade) at P value < 0.0005,
moderate significance (medium
colour shade) at P value < 0.005
and acceptable significance at
(low colour shade) at P value <
0.05. P value ≥ 0.05 was not
considered significant (grey bars).
Each dot is a mouse and whiskers
represent mean ± SD
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confirmed that STAT3 and RUNX1 were expressed in
mIMCD3 cells (Supplementary Fig 3). We then isolated chro-
matin and performed ChIP-qPCR. STAT3 enrichment at the
promoter region of the Scp2,Kif22, Stat3 and Socs3 genes was
significantly higher than at nonbinding regions (Fig. 5a). Also,
RUNX1 showed significant enrichment at the promoter re-
gions of its targets Runx1, Tnfrsf12a and Bcl3 (Fig. 5b) com-
pared to nonbinding regions.
Thus, we can conclude that STAT3 and RUNX1 are active-
ly binding the selected target genes in renal epithelial cells.
Stat3 and Runx1 ChIP-qPCR in murine kidney tissue
We then investigated whether binding of STAT3 and
RUNX1 at the promoter region of their target genes is in-











































































































Fig. 5 ChIP validation of
pSTAT3 and RUNX1 targets in
mIMCD3 cells. a ChIP with anti-
pSTAT3 antibody showed signif-
icant enrichment at the promoter
region of Scp2, Kif22, Stat3 and
Socs3 compared to a negative
control antibody (rIgG) and a
nonbinding region (Neg). b ChIP
with anti-RUNX1 antibody
showed a significant enrichment
at the promoter region of Runx1,
Tnfrsf12a and Bcl3 compared to a
negative control antibody (mIgG)
and a nonbinding region (Neg).
The Y-axis shows the input-
normalised binding-enrichment
of the TFs to the indicated geno-
mic region. Data represent the
mean of two independent ChIPs ±
SD; Two-way ANOVAwith
Tukey’s multiple comparisons
test. *P value < 0.05; **P value <
0.01; ***P value < 0.001
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To do so, we performed ChIP-qPCR using kidneys from
iKspPkd1del mice, harvested at kidney failure, as well as
age- and treatment-matched Wt kidneys.
As expected, we observed a significantly increased abun-
dance of STAT3 at Stat3, Socs3, Scp2 and Kif22 promoter
regions in iKspPkd1del mice compared to Wt (Fig. 6a, more
severe iKspPkd1del + DCVC and Supplementary Fig. 4a,
milder iKspPkd1del + PBS).
RUNX1 enrichment in iKspPkd1del mice was not signifi-
cantly higher than in Wt mice. However, RUNX1 enrichment
was significantly higher compared to IgG at the promoter
region of Runx1 and Bcl3 in iKspPkd1del mice but not in
Wt. A similar trend is observed for Tnfrsf12a. This means that
in iKspPkd1del mice, RUNX1 binding is specific, while inWt,
it is not different from the background signal. Thus, RUNX1

















































































































Fig. 6 Increased binding of
STAT3 and RUNX1 to the
promoter of target genes in cystic
kidneys, shown by ChIP-qPCR.
ChIP-qPCR analysis of end-stage
renal disease iKspPkd1del kidneys
or Wt kidneys at 24 weeks after
DCVC. a We confirmed an in-
creased enrichment for STAT3
binding at target genes in
iKspPkd1del kidneys compared to
Wt kidneys. b RUNX1 enrich-
ment at its targets is not detected
in Wt samples (no difference be-
tween RUNX1 ChIP and IgG
ChIP) but detected in iKspPkd1del
samples. Black bars pSTAT3 or
RUNX1 antibody, grey bars
isotype IgG control (rIgG, rabbit
IgG; mIgG, mouse IgG). The Y-
axis shows the input-normalised
binding-enrichment of the TFs to
the indicated genomic region.
Data represent the mean of two
independent ChIPs ± SD; Two-
way ANOVAwith Tukey’s mul-
tiple comparisons test. *P value <




more severe iKspPkd1del + DCVC and Supplementary Fig.
4b, milder iKspPkd1del + PBS).
Overall, these data, in addition to the altered expression
levels, show that the activity of STAT3 and RUNX1 is in-
creased in advanced stages of PKD in mice.
Expression of TFs in kidneys of ADPKD patients
Lastly, we checked the expression of STAT3 and RUNX1 in
human kidney sections obtained from ADPKD patients and
healthy controls. Comparably with what was observed in
mice, in healthy controls, we found only sporadic expression
of pSTAT3 in the nuclei of tubular epithelial cells (Fig. 7,
asterisks) and expression of RUNX1 in some infiltrating cells
(Fig. 7, arrowheads). Conversely, in ADPKD patients’ renal
tissue, the expression of pSTAT3 and RUNX1 was increased
in the nuclei of the epithelial cells and infiltrating cells (Fig. 7,
right panel and Supplementary Fig. 5, right panel).
These data suggest that the TFs identified by our meta-
analysis using rodent models are relevant for human ADPKD.
Discussion
Previously, we identified a list of 1515 genes dysregulated
during PKD progression, which we defined as PKD
Signature. We also showed a consistent overlap (about 35%)
of the PKD Signature with genes normally involved in injury/
repair mechanisms [5]. Now, we have put this analysis a step
further by identifying and characterising TFs involved in
ADPKD progression.
Using MSigDB, we identified 92 TFs in the PKD
Signature and again showed that about 35% of these genes
(32 out of 92) have a strong injury-related component. This is
in line with a substantial body of literature indicating that
injury is a significant modifier in PKD and a potential trigger
of cyst formation. Indeed, renal injury causes faster cystic
disease progression suggesting that events activated during
the injury/repair phase are also crucial for cyst initiation and
expansion [3, 4]. Moreover, cyst formation per se is a source
of injury for the surrounding tissue making the two patholog-
ical processes challenging to dissect [19].
Among these 92 identified TFs, we observed known
players in PKD, such as STAT3 [17, 20], c-MYC [18],
SMAD2 [21], GLIS2 [22], c-JUN [23] and E2F1 [24],
confirming our approach. On the other hand, we did not find
TFs such as PPARα, which has been described to play a role
in PKD [25]. This is likely due to the high stringency used for
the definition of the PKD Signature, which allows us to get
specific targets while possibly losing others [5].
Interestingly, we also identified many other TFs, never de-
scribed before in PKD. Some of these TFs, such as EGR1,
KLF5 and FOXM1, have been reported in literature for their
involvement in injury/repair mechanisms or pathways dysreg-
ulated during PKD progression and might be interesting can-
didates for future studies. Indeed, Egr1 is an early growth
response gene and is downstream of the mitogen-activated
protein kinase (MAPK) pathway, a pathway dysregulated in
PKD [23]. EGR1 is a key regulator of proliferation, apoptosis
and inflammation and was shown to be involved in renal
injury and fibrosis. Egr1 disruption protected mice from renal
failure in a model of tubulointerstitial nephritis and resulted in
lower activation of the TGF-β pathway [26]. Moreover, Egr1
can be downregulated by curcumin, a compound able to re-
duce cyst formation in vivo [17]. Also, KLF5 was shown to
play a role in renal inflammation and fibrosis since unilateral
Fig. 7 pSTAT3 and RUNX1
expression in human kidneys with
ADPKD. Representative
immunohistochemistry of human
kidneys. In healthy patients, the
expression of pSTAT3 and
RUNX1 was rarely detected
(asterisks). In end-stage cystic
kidneys from ADPKD patients,
pSTAT3 and RUNX1 localised in
the nuclei of the tubular epithelial
cells (arrows) and infiltrating cells
(arrowheads). Scale bars 100 μm
55
Characterization of Transcription Factor Profiles in Polycystic Kidney Disease (PKD): 
Identification and Validation of STAT3 And RUNX1 in the Injury/Repair Response and PKD Progression 
ureteral obstruction in mice haploinsufficient for Klf5 resulted
in reduced renal injury, fibrosis and infiltrating cells [27].
Thus, modulation of KLF5 activity might improve the pro-
fibrotic and pro-inflammatory phenotype observed especially
during the more advanced phases of PKD progression. Foxm1
is expressed during cell proliferation and is critical for cell
cycle progression. In adult tissues Foxm1 expression is low,
but after injury, its levels are dramatically increased. In partic-
ular, FOXM1 can control the expression of genes involved in
the G2/M transition phase. Cell-cycle arrest in G2/M phase is
associated with pro-fibrotic cytokines production by proximal
tubular cells [28]. Not surprisingly, these three TFs are in-
volved in PKD since aberrant extracellular matrix (ECM) de-
position is commonly found in PKD patients and animal
models of PKD, not only in ESRD but also in early stage
[29]. This suggests that increased ECM deposition may be
contributing to cyst formation and not barely be a conse-
quence of it, as shown for laminin-alpha5 [30] and integrins-
beta1 [31], which mutation could affect the cystic phenotype.
Thus, modulation of pro-fibrotic processes could be a valuable
strategy to modulate PKD progression.
EGR1, KLF5 and FOXM1, together with ESR1 and
STAT3, were also among the significantly enriched PKD
Signature TFs identified based on their target genes annotated
in the ChEA 2016 database. Pathway analysis of the targets of
these TFs, using Genetrail2 and Wikipathways, revealed en-
richment for pathways known to play a role in PKD progres-
sion, such as the TGF-β pathway, oxidative stress, cellular
metabolism, interleukins signalling, adipogenesis, estrogen
signalling and apoptosis [21, 32–35]. Using this approach,
we also identified TFs not directly present in the PKD
Signature. Interestingly, the top five TFs identified based on
their targets were all described in literature to be involved in
the progression of PKD (STAT3)[17, 20, 36] or in processes
relevant for PKD like angiogenesis (E2F7)[37], DNA damage
response (E2F7, TRIM28)[38, 39], renal injury and fibrosis
(EGR1)[26], epithelial cell proliferation, apoptosis and adhe-
sion (TP63)[40]. Nevertheless, apart from STAT3, the TFs
themselves had never been associated with PKD before and
therefore could be interesting subjects for future studies.
Surprisingly, we did not find back RUNX1 in this list as the
level of enrichment was just below the significance threshold
(data not shown). Nevertheless, we confirmed increased ex-
pression and activity of RUNX1 during PKD progression in
mice and humanADPKD kidneys. Thus, we speculate that the
absence of RUNX1, as well as other TFs potentially involved
in PKD, is due to limitations related with the ChEA database,
such as the source of ChIP-data, the way the different studies
have been analysed and the actual TFs included in the
database.
To further test and validate our approach, we selected for
additional wet-lab validation STAT3 and RUNX1 as they
showed the most significant change in expression both in
PKD progression and injury. By performing ChIP-qPCR for
STAT3 and RUNX1 in ADPKD-affected kidneys, we con-
firmed increased transcriptional activity in cystic kidneys for
these TFs. Persistent activation of STAT3 has been described
in several mouse models for ADPKD as well as in human
cystic tissues [17, 20, 36]. STAT3 usually is not active in adult
kidneys but is abundantly present, suggesting that it can be
readily activated at needs, such as after injury [36]. Indeed,
STAT3 activation has been shown in several different mouse
models with renal injury [41, 42]. Thus, the fact that we found
back STAT3 and several of its putative targets in our signature
proved the reliability of our meta-analysis.
RUNX1 involvement in ADPKD has never been described
before. RUNX1 is one of the Runt domain TFs, together with
RUNX2 and RUNX3. RUNX2 expression has been shown to
be regulated by PC1 in osteoblasts, proving the existence of an
interaction between the two proteins [43]. Nevertheless, ex-
pression of RUNX2 or RUNX3 is not increased after injury
nor during disease progression in murine (cystic) kidneys
(RNA-Seq data identifier E-MTAB-5319 published in Malas
et al., 2017 [5]). RUNX1 is expressed in the epithelium of
several organs during development, among which the kidneys
[44]. It participates in the regulation of cell cycle, cell prolif-
eration and apoptosis [45] and has been described in several
models for lung, muscle and brain injury [46–48]. Recently, a
study was published suggesting that RUNX1 is an important
regulator of TGF-β-induced renal tubular epithelial-to-
mesenchymal transition (EMT) and fibrosis [49]. As men-
tioned above, TGF-β signalling is involved in ECM deposi-
tion and cyst progression and is partly responsible for the
EMT observed in cystic kidneys. Modulation of TGF-β-
related signalling is associated with amelioration of the cystic
phenotype [21]. Thus, it is plausible that RUNX1might play a
role in ADPKD progression. In fact, inhibition of STAT3 sig-
nalling with more or less specific inhibitors, such as curcumin,
pyrimethamine and S3I-201, has been proven to improve the
cystic phenotype in different mouse models [17, 20, 36].
Similarly, we propose that targeting RUNX1, for example,
using microRNAs as described for prostate cancer [50], or
other molecular or pharmacological approaches, might also
result in amelioration of the cystic phenotype.
We observed increased expression of STAT3 and RUNX1
also after injury in Wt mice, suggesting that these TFs orches-
trate injury/repair mechanisms and that increased expression
is not necessarily related to Pkd1 deletion. Notably, dissecting
PKD progression and injury is not easy, since injury can speed
up cyst initiation/growth, which in turn causes injury to the
surrounding tissue. Therefore, it is plausible that both STAT3
and RUNX1 are facilitating PKD progression by activating
injury/repair pathways normally inactive in fully developed
and healthy kidneys.
To conclude, our comprehensive analyses identified a sig-
nature of TFs differentially expressed in PKD and to a certain
56
Chapter 3
extent also in injury/repair. Several of these TFs are involved
in processes able to support cyst formation and progression,
nevertheless were never described before in PKD, suggesting
that they might be interesting targets for therapy. However,
further analyses are needed to identify the molecular pathways
that these TFs modulate to contribute to PKD progression and
cyst formation. Additionally, the TFs we identified are a sub-
set of the TFs involved in PKD and not a comprehensive list.
This is due to limitations in the annotation databases we used
and RNA-Seq technology. To establish a comprehensive list
of TFs involved in PKD and/or injury, further studies must be
conducted on protein levels and protein phosphorylation sta-
tus. That said, our approach was capable of robustly identify-
ing 92 TFs, and additional wet-lab validations confirmed the
involvement of RUNX1 and STAT3 making this paper a
starting point to understand the role of TFs in PKD
progression.
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A B S T R A C T
Background: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is one of the most common causes of
end-stage renal failure, caused by mutations in PKD1 or PKD2 genes. Tolvaptan, the only drug approved for
ADPKD treatment, results in serious side-effects, warranting the need for novel drugs.
Methods: In this study, we applied RNA-sequencing of Pkd1cko mice at different disease stages, and with/
without drug treatment to identify genes involved in ADPKD progression that were further used to identify
novel drug candidates for ADPKD. We followed an integrative computational approach using a combination
of gene expression profiling, bioinformatics and cheminformatics data.
Findings: We identified 1162 genes that had a normalized expression after treating the mice with drugs
proven effective in preclinical models. Intersecting these genes with target affinity profiles for clinically-
approved drugs in ChEMBL, resulted in the identification of 116 drugs targeting 29 proteins, of which several
are previously linked to Polycystic Kidney Disease such as Rosiglitazone. Further testing the efficacy of six
candidate drugs for inhibition of cyst swelling using a human 3D-cyst assay, revealed that three of the six
had cyst-growth reducing effects with limited toxicity.
Interpretation: Our data further establishes drug repurposing as a robust drug discovery method, with three
promising drug candidates identified for ADPKD treatment (Meclofenamic Acid, Gamolenic Acid and Birinapant).
Our strategy that combines multiple-omics data, can be extended for ADPKD and other diseases in the future.
Funding: European Union’s Seventh Framework Program, Dutch Technology Foundation Stichting Technische
Wetenschappen and the Dutch Kidney Foundation.










Drug repurposing, defined as the application of known drugs and
compounds to treat new indications, is seen as a bypass for the long
and expensive process of developing new drugs. Estimates show that
drug repurposing can save more than 50% of the cost and time
needed to develop new drugs [1]. In the past, accidental discovery,
unintended side effects or obvious follow-on indications have led to
new uses of such drugs [2]. Notable examples of drug repurposing
include, Minoxidil (originally tested for hypertension; now indicated
for hair loss) and Viagra (originally tested for angina; now indicated
for erectile dysfunction and pulmonary hypertension). Current drug
repurposing efforts span the spectrum from blind screening chemical
libraries against specific cell lines [3] or against cellular organisms
[4], to serial testing in animal models [5], and to data-driven compu-
tational methods [6]. The latter category explores the fact that a sin-
gle molecule can act on several targets, making it valuable to
indications where these targets are also relevant [7]. Gene expression
profiles generated with expression microarrays or RNA-sequencing,
have been used for the identification of druggable targets and path-
ways [810] and are suited for the identification of drug repurposing
candidates under the assumption that diseases that share aberrant
molecular processes may be targeted by the same drugs. However,
gene expression profiles have mainly be used in isolation and
* Corresponding author: Dorien J.M. Peters, Department of Human Genetics, Leiden
University Medical Center, Leiden, The Netherlands.
E-mail address: d.j.m.peters@lumc.nl (D.J.M. Peters).
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integrative approaches where gene expression profiles are combined
with other information are scarce.
Here we have undertaken a novel approach to repurpose drugs for
the treatment of Autosomal Dominant Polycystic Kidney Disease
(ADPKD). ADPKD is a genetic disease of the kidney, with a prevalence
of 4 to 10/10,000, it is one of the most common causes of end-stage
renal failure [11,12]. ADPKD is characterized by the gradual replace-
ment of normal kidney parenchyma by fluid-filled cysts and fibrotic
tissue with age, ultimately leading to end-stage renal disease in most
patients. The main genes mutated in patients with ADPKD are the
PKD1 and PKD2 genes [13]. ADPKD shows variable disease progres-
sion, with 50% of patients developing end-stage kidney disease by
the age of 60. While advances have been made in slowing the pro-
gression of some other forms of chronic kidney disease, standard
treatments have not reduced the need for renal replacement therapy
in ADPKD [14,15]. Unfortunately, several experimental interventions
have recently failed to show significant benefit in slowing the rate of
functional decline [1618], while the interventions with positive
outcomes, including the approved drug Tolvaptan, reported modest
effects [19,20].
The difficulty in identifying drugs for ADPKD treatment can be
partially attributed to the lack of understanding of the functions of
the PKD1 and PKD2-gene products, and on how their inactivation
leads to cyst development. Strategies are focused on therapies that
can slow the rate of disease progression in PKD patients. The identifi-
cation of more and better drugs would require a macro-level under-
standing of the key molecular pathways contributing to cyst
initiation and growth in patients and animal models. Transcriptomics
deep-sequencing of disease states was proven successful in identify-
ing promising drug candidates in several examples [21,22].
By sequencing mild, moderate and advanced stages of ADPKD
mouse models, we identified genes involved in ADPKD progression.
To further validate these genes involvement in disease progression,
we compared their expression to the expression profiles of drug-
treated ADPKD mouse models and looked-for gene expression altera-
tions that are normalized after drug treatment. These genes have
been included in a drug repurposing analysis in which targets of
drugs published in ChEMBL have been compared to our expression
profiles. This resulted in the identification of several drugs that
potentially can be repurposed for ADPKD. We validated several of
these compounds in a 3D cyst culture assay and propose them as
potential candidates for ADPKD treatment (Supplementary Figure 1).
2. Materials and methods
2.1. Animal models and drug treatments
2.1.1. Mice used in the ADPKD progression analysis
The inducible kidney-specific Pkd1-deletion mouse model (tam-
KspCad-CreERT2;Pkd1lox2-11;lox2-11, referred to as iKsp-Pkd1del) and
tamoxifen treatments have previously been described [23]. In this
study mutant mice are called Pkd1cko mice. RNA sequencing was
done on kidneys from 5 adult Wild-type (Wt) mice and 24 iKsp-
Pkd1del mice with tamoxifen-induced gene disruption at the age of 38
or approximately 90 days (Mutant). Four mice per group were sacri-
ficed at 2wk, 3wk and 6wks after tamoxifen administration. Five
mice were sacrificed at 11wk of age, 4 at 12wk of age and 3 mice at
15wk after tamoxifen administration (Supplementary Table 1, Sup-
plementary Figure 2). In addition, a young PKD model was analyzed
with tamoxifen treatment at postnatal age of 10 days, as previously
described [24], and the kidneys were harvested at age of 4.7 weeks
(n = 3). Blood sampling and blood urea measurements were per-
formed using Reflotron technology (Kerkhof Medical Service) as
described previously [25]. Only male mice were used.
2.1.2. Ethics statement
All the animal experiments were evaluated and approved by the
local animal experimental committee of the Leiden University Medi-
cal Center (LUMC) and the Commission Biotechnology in Animals of
the Dutch Ministry of Agriculture.
2.1.3. Drug treated mice
Rapamycin (Sirolimus), Curcumin and soluble activin receptor IIB
Fc (sActRIIB-Fc) treated Pkd1cko mice and controls were previously
published [23,24,26] (Supplementary Figure 2).
2.1.4. Measurement of disease progression in ADPKD model
2KW/BW was used as measurement for disease severity and
strongly correlated with the cystic index (Supplementary Figure 3).
2.2. Statistical analysis
2.2.1. Processing of RNA sequencing samples
RNA sequencing was performed on the Illumina HiSeq 2500.
The Illumina mRNA-Seq Sample Prep Kit was used to process the
sample according the Illumina protocol "Preparing Samples for
Sequencing of mRNA" (1,004,898 Rev. D). Briefly, mRNA was iso-
lated from total RNA using the oligodT magnetic beads. After frag-
mentation of the mRNA, a cDNA synthesis was performed. This was
used for ligation with the sequencing adapters and PCR amplifica-
tion of the resulting product. The quality and yield after sample
preparation were measured with a DNA 1000 Lab-on-a-Chip (Agi-
lent Technologies). The size of the resulting products was consistent
Research in context
Evidence before this study
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a
progressive kidney disease, with 50% of patients reaching end-
stage kidney disease at the age of 55. Fluid-filled cysts that
gradually replace normal kidney parenchyma, accompanied by
massive fibrosis, are identified as the main cause of renal fail-
ure. Tolvaptan is currently the only approved drug for ADPKD
treatment, but with serious side-effects (i.e. diuresis). There-
fore, there is a need for drugs that specifically target the forma-
tion and growth of cysts, to slow down or halt disease
progression.
Added value of this study
Using a novel approach that combines bio and chemo-infor-
matics, we repurpose drugs for the treatment of ADPKD. We
compared transcriptomic data of ADPKD mouse models at
different disease stages, as well as before and after drug
treatment, to identify genes that are involved in ADPKD
progression. By screening the ChEMBL drug-protein interac-
tion database, we prioritized a list of candidate drugs that
target ADPKD progression-associated genes. Finally, we
showed that three out of six selected candidate compounds
exhibit cyst-growth reducing effects in vitro, without toxic
effects.
Implications of all the available evidence
We have identified three novel compounds that could be further
investigated and developed for the treatment of ADPKD, these
are Meclofenamic Acid, Gamolenic Acid, and Birinapant. Further-
more, our approach is applicable to other diseases, provided that
high quality transcriptomic/proteomics data is available for inte-
gration with large scale drug affinity and activity data.
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with the expected size distribution (a broad peak between
300500 bp on a DNA 1000 chip). Clustering and DNA sequencing
using the Illumina cBot and HiSeq 2500 was performed according to
manufacturer’s protocols. A concentration of 15.0 pM of DNA was
used. Detailed run information per group is provided in Supplemen-
tary Table 1. HiSeq control software HCS v2.2.38 was used. Image
analysis, base calling, and quality check was performed with the
Illumina data analysis pipeline RTA v1.18.64 and Bcl2fastq v1.8.4.
All samples had a quality score Q30 for more than 93.6% of reads.
Resulting reads were aligned to the mouse reference genome ver-
sion GRCm38 using Tophat v.2.0.12 with default parameters [27].
The only exception is the use of the no-coverage-search which does
not perform an initial coverage search against the genome, thus
reducing substantially the computational time. After alignment,
HTSeq-count (Version 0.6.1) was used to estimate gene expression
by counting reads that were mapped to the reference genome
GRCm38 exons of each gene using the following options: -s
(stranded) = no, -a (mapping quality) = 10, -m (mode) = intersec-
tion-nonempty, -i (identification) = gene_id -t (feature to count) =
exon. Gene counts were transformed to Counts Per Million (cpm)
values and then normalized using the TMM normalization method
from the edgeR package (Robinson, McCarthy et al., 2010) (version
3.2) was used. Normalized genes were then used as an input for the
Voom transformation method implemented in the limma package
[28] in R 3.4.4. Genes with low expression values (cpm < 2 in more
than 50% of the samples) were excluded from differential gene
expression analysis. A linear-model was fit and differentially
expressed genes were calculated across all samples involved in
ADPKD progression and treated vs. untreated ADPKD samples. Raw
data was deposited in ArrayExpress and given the following identi-
fier E-MTAB-8086.
Validation datasets [15,29] were acquired from GEO (ID:
GSE72554 and GSE7869) and further processed using limma for the
identification of the differentially expressed genes in each of the dif-
ferent mice groups. For the data of Menezes et al., we compared the
resultant lists of differentially expressed genes with the different
clusters involved in ADPKD progression using the representation fac-
tor. The representation factor is the number of overlapping genes
divided by the expected number of overlapping genes drawn from
two independent groups. A representation factor > 1 indicates more
overlap than expected of two independent groups, a representation
factor < 1 indicates less overlap than expected, and a representation
factor of 1 indicates that the two groups have the same overlap for
independent groups of genes. For the data of Song et al., we combined
the differentially expressed genes (P-value < 0.05, t-statistics) of the
small and medium cysts and processed them using the method
detailed in “Annotation of Gene Expression Profiles” sub-section.
2.2.2. Principal component analysis (PCA)
Samples involved in ADPKD progression were selected and pre-
pared for Principal Component Analysis (PCA). Briefly, the above
noise level voom-transformed gene expression values were orga-
nized in a data matrix and given as an input for the ir.pca function in
R. The loadings of the different principal components were plotted in
a 2-dimensional plot using the ggplot2 package in R.
2.2.3. Gene expression clustering
Hierarchical clustering was applied on all differentially expressed
genes resulting from the pairwise comparisons of all samples
involved in ADPKD progression (FDR < 0.005, Supplementary Table
1). The hclust package in R was applied on the euclidean distance
matrix calculated using the dist R function. Utilizing the cutree func-
tion implemented in R, the resultant clustering tree was cut into 15
clusters. For each cluster, all gene members were plotted. In addition,
the average gene expression pattern was based on the averaged
expression values at each time-point.
2.2.4. Annotation of gene expression profiles
We annotated the resulting gene expression profiles using the
GeneTrail2 v1.5 tool [30]. We ran the over-representation analysis
against the Wikipathways database. We used all expressed genes
above noise level as background and accepted enriched terms with
P-value < 0.05.
2.2.5. Drug targets acquisition and prioritization
All high quality data on the selected protein targets were acquired
from ChEMBL release 22 [31]. High quality was defined as follows:
data points with a ChEMBL confidence score of 9 (direct single pro-
tein target assigned), with a pChEMBL activity value, and having >=
30 compound measurements per protein. The pChEMBL value is the
negative logarithm of activity in molar for curve fitted activity values
such as Ki, IC50, EC50, AC50, XC50. Furthermore, only human pro-
teins were considered. This led to a total of 990 protein targets
(directly assigned targets), and 356,396 interactions with 240,433
compounds. Mus musculus gene identifiers were converted to the
homologous homo sapiens identifiers using the BioMart tool on the
Ensembl website [32], and cross-checked with the Homo sapiens drug
targets. We prioritized the resulting drug targets from the ChEMBL
database [33] through several filtering steps based on a couple of cri-
teria. First the overlap between this set and the PKD progression
genes was kept, a total of 168 protein targets with 54,698 annotated
bioactivities, through 48,050 small molecules. Subsequently only
drug targets that were annotated to small molecules that have been
tested in phases 2, 3 or 4 of clinical trials were kept. This was aimed
at keeping molecules that have passed phase 1, which is aimed at
determining if a drug is safe for efficacy testing in phases 2 and 3,
phases 4 represents approved and marketed drugs. Secondly, we fil-
tered targets that have antineoplastic activity based on the Anatomi-
cal Therapeutic Chemical (ATC) Classification System [https://www.
who.int/classifications/atcddd]. Thirdly, for all remaining drugs and
targets, we investigated for each drug, its mode of action in relation
to each of its remaining targets and compared this to the direction of
deregulation in the PKD Progression. When a drug has a conflicting
mode of action to what is needed to correct the target’s expression in
ADPKD, that drug received low priority. For example, if drugA is an
agonist to an up-regulated target in PKD, drugA would be excluded
(or receive low priority). We kept the drugs that did not have a
known mode of action. Fourthly, for the remaining targets, we gave
the highest priority to drug targets that were dysregulated in the
early phases of the disease, followed by moderate phases and finally
advanced phases.
2.3. 3D cyst drug screening
The 3D cyst culture assay has been performed with Pkd1-KO
mouse-inner medullary collecting duct (mIMCD3) cells (mIMRFNPKD
5E4) as described previously [34]. In short: mIMRFNPKD cells were
mixed with Cyst-Gel (OcellO, Leiden, The Netherlands) to a final con-
centration of 150,000 cells/mL. 15ml of cell-gel mix was pipetted to
384-well plates (Greiner Clear, Greiner Bio-One B.V.) using a CyBio
Felix 96/60 robotic liquid dispenser (Analyik Jena AG). After gel poly-
merization at 37 °C for 30 min, 33 mL culture medium was added to
each well. Cells were grown in gel for 96 h, after which the cells were
co-exposed with forskolin (Calbiochem) and one of the following
molecules: Rapamycin (SelleckChem, S1039), Staurosporin (Selleck-
Chem, S1421); Birinapant (Bioconnect, PK-CA577-25971), Gamma-
Linolenic acid (Sanbio, 90,22050), Eicosapentaenoic acid (Sanbio,
90,11050), Meclofenamic Acid (Sanbio, 70,5501), Zileuton (San-
bio, 10,006,96710) and Indometacin (Sanbio, 70,2701). Rapamy-
cin and Staurosporin were used as cyst swelling inhibiting or toxic
control respectively. All conditions were tested in quadruplicate.
After 72 h, cultures were fixed with 4% Formaldehyde (Sigma Aldrich)
and simultaneously permeabilized with 0.2% Triton-X100 (Sigma
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Aldrich) and stained with 0.25 M rhodamine-phalloidin (Sigma
Aldrich) and 0.1% Hoechst 33,258 (Sigma Aldrich) in 1x PBS
(Sigma Aldrich) for 12 h at 4C, protected from light. Imaging was
done using Molecular Devices ImageXpress Micro XLS (Molecular
Devices) with a 4x NIKON objective. For each well, 30 images in the
Z- direction (50 mm apart) were made for both channels. Each image
captures the whole well area. Image analysis for actin and nuclei was
performed using Ominer analysis software (OcellO BV.) integrated in
KNIME Analytics Platform (Konstanz, Germany, http://www.knime.
org/). Further data analysis was also done in KNIME. The main read-
out for efficacy, “cyst area”, was calculated per well as the average of
the area in px of each object in every in-focus plain. This measure-
ment was then normalized to positive (100%) and negative control
(0%). The parameters used for toxicity; “nuclei area” and “nuclei
roundness” were calculated in a similar fashion, “fraction apoptotic
nuclei” was calculated as the amount of nuclei without actin signal
relative to the total amount of nuclei, both as count-measurements.
Graphs were made in Graphpad 6 (GraphPad Software, La Jolla, CA).
3. Results
3.1. Gene expression patterns associated with disease severity
To study the different phases of ADPKD progression, we have
inactivated Pkd1 at postnatal day 38 or 90 (adult phase) in the kid-
neys and harvested these animals at different time points after gene
inactivation, resulting in five groups of mice with different disease
stages. In these mice the largest group of cysts originate from the
proximal tubules but cyst are also formed in distal tubules and col-
lecting ducts [35]. Pkd1cko animals sacrificed after 2, 3 or 6 weeks
after gene inactivation represent very early disease states. Pkd1cko
animals sacrificed at 11 and 12 weeks after gene inactivation repre-
sent a moderate state of the disease and Pkd1cko animals sacrificed at
15 weeks after gene inactivation represent advanced disease. The
kidney weight to body weight ratios (2KW/BW) of the five groups
concurred with increasing disease severity in these samples (Fig. 1A,
Supplementary Table 1).
We carried out RNA sequencing of the different groups of mice
(Supplementary Figure 1). RNA was extracted from the five Pkd1cko
and wild-type (WT) groups and cDNA sequenced on the Illumina
2500 Hiseq platform. Applying principal component analysis (PCA)
on the gene expression profiles of these samples and plotting the first
components revealed that most of the variance between samples
could be attributed to differences in disease severity (principal com-
ponent-1 (pc1), explaining 28% of the total variance, Fig. 1B). Extract-
ing the 20 most influential genes in component-1 and plotting their
expression in all disease progressing samples showed that these
genes strongly correlated with disease progression (average Spear-
man's rank correlation coefficient = 0.7; Fig. 1C). Components-2 and
3 explained 26.7% and 8.3% of the variance respectively, where com-
ponent 3 may reflect the variation between different mice.
3.2. Expression patterns associated with ADPKD progression
To gain fine-grained insights into the different patterns of gene
expression during disease progression, we applied hierarchical clus-
tering on the 2731 differentially expressed genes (FDR < 0.005) dis-
criminating the groups of mice in different states of disease
progression. In the first round of clustering we grouped the 2731 dif-
ferentially expressed genes based on their expression patterns across
the different disease progression stages into 15 clusters. This resulted
in 12 gene clusters with distinct and coherent expression profiles,
ranging in size from 32 to 367 genes. Additionally, three clusters con-
tained genes that showed an aberrant pattern in just one of the sam-
ples. These clusters (cluster 3, 11 and 14) were removed from further
analysis (Fig. 2A, Supplementary Table 2). The remaining 12 clusters
were characterized by their gene expression patterns. For example,
cluster 1 shows up-regulation in the early pre-cystic phases of the
disease, particularly at 2wk, 3wk and 6wks after gene inactivation.
Cluster 4 on the other hand includes genes that are up-regulated in
the moderate phase of the disease starting from 11 weeks of gene
inactivation. Cluster 10 is an example of a cluster that contains genes
that are down-regulated in the advanced stages of the disease, at
1215 weeks after gene inactivation. As we are interested in the
three distinct phases of the disease (i.e. early, moderate or advanced),
we further grouped the 12 clusters into 3 groups, where each of the
new groups represents one of the three distinct phases, with genes
up- or down- regulated particularly in early (n = 5 clusters), moderate
(n = 4 clusters) or late (n = 3 clusters) phases of disease (Fig. 2A).
3.3. The expression patterns can be replicated in an independent study
Menezes et al. recently published a study of a different Pkd1
knockout mouse model for ADPKD [15]. They included mouse sam-
ples at different disease stages namely, pre-cystic, cystic and severely
cystic. We tested the statistical enrichment, using the representation
factor (RF) method, of the genes in each of our three disease-stage
groups were compared to the genes that are differentially expressed
in pre-cystic, cystic and severely-cystic male mice of Menezes et al.
As expected, the early dysregulated group demonstrated the stron-
gest overlap with the pre-cystic groups in Menezes et al. study
(Fig. 2B). Likewise, the moderate stage group showed greater overlap
in the cystic and severely cystic groups. Similar patterns were
observed in the advanced gene group, which was most consistent
with the cystic and severely cystic groups (Fig. 2B). The strong over-
lap observed across disease stages was more evident in the up-regu-
lated clusters compared to the down-regulated clusters. Taken
together, these results reflect strong reproducibility of the expression
patterns in an independent study. Since 2KW/BW is an accepted
measurement of ADPKD disease stage and progression, we correlated
the expression values in the 12 distinct clusters with 2KW/BW. The
spearman coefficient plotted in Fig. 2C showed strong correlation of
moderate and advanced stage clusters with 2KW/BW, while the early
phase clusters had a weak correlation with 2KW/BW. This is
expected, because the early ADPKD samples have 2KW/BW similar to
that of the wild types.
3.4. Biological functions and pathways associated with ADPKD
progression
To understand the biological functions involved in ADPKD progres-
sion, we looked for the over-represented pathways in each of the three
disease phases, early, moderate and advanced. For each disease phase,
we combined the genes of the clusters that belonged to that phase and
used GeneTrail2 v1.5 Wikipathways database to annotate them
(FDR < 0.05). Terms enriched (FDR < 0.05) in any of the three disease
phases are shown in Fig. 3A and provided as Supplementary Table 3.
Hierarchical clustering was used to distinguish pathways that were
specifically enriched in the early, moderate or late phases of the dis-
ease, and the pathways that were dysregulated across all phases
(Fig. 3B). Interestingly, even at the pre-cystic phases we observed dys-
regulation in metabolism in the form of dysregulated TCA cycle and
fatty acid biosynthesis, as well as Wnt signaling. Additionally, we
observed dysregulation in G13 signaling pathway that is involved in
cytoskeletal remodeling in cells and is essential for receptor tyrosine
kinase-induced migration of fibroblast and endothelial cells. In the
moderate and advanced phases of the disease, proliferation-related
and inflammation-related pathways were dominant. The oxidative
stress pathway, p53 and DNA mismatch-repair pathways were clearly
visible in the advanced phase, along with alterations in metabolism.
TNFa and chemokine signaling were active during all phases, from
pre-cystic to advanced PKD. Using the work of Song et al. 2009 as a
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reference for human ADPKD, we confirmed the dysregulation of sev-
eral of the aforementioned pathways in PKD patients. These include
TCA cycle alterations, aberrant metabolism, active cytoskeleton
remodeling and inflammation (Supplementary Table 3D).
3.5. Further selection of the ADPKD progression genes by evaluating
response to therapy
We have previously shown that treating Pkd1cko P40 mice with
Rapamycin and Curcumin and Pkd1cko P10 mice with soluble activin
receptor IIB Fc (sActRIIB-Fc) significantly reduced kidney size and
slowed the progression of ADPKD in mice [23,24,26] (Table 1). Here,
we sequenced the RNA of the kidneys of these drug-treated mice
using Illumina 2500 Hiseq platform and identified the differentially
expressed genes (DEGs) between the treated and untreated samples.
The curcumin treated samples are Pkd1cko P40 mice harvested at 11
weeks of age after gene inactivation; the same mouse model was
treated with Rapamycin and harvested at two time-points, 12 weeks
and 15 weeks after gene inactivation (Supplementary Figure 2). The
soluble activin receptor-Fc fusion (sActRIIB-Fc) treatment was given
to Pkd1cko P10 mice at two different time-points after tamoxifen
treatment, starting at 0.3 weeks for the early-treated samples and at
2.1 weeks for the late treated mice (Supplementary Figure 2). Both
groups were harvested at 4.1 weeks of age.
To balance the analysis between the different treatment groups,
we took equally sized lists of the most differentially expressed genes
(sorted on P-value). The size of the gene list was based on the treat-
ment group with the lowest number DEGs (i.e. sActRIIB-Fc treat-
ment), which is equal to 840 genes (P-value < 0.05 t-statistics,
Table 1). For 1162 out of the 2731 genes that we identified to be
Fig. 1. Kidneys taken out at various disease stages show differences in expression profiles. (a) Boxplot representation of the 2KW/BW values for groups of Pkd1ckomice representing
different phases of ADPKD with increasing disease severity. (b) Results from principal component analysis of the Pkd1cko samples. Shown are the loadings of plot of pc1 (x-axis) and
pc3 (y-axis) of all samples. In the panel the samples are colored based on their 2KW/BW value. (c) Boxplots of the top 10 most up-regulated (left part) and the 10 most down-regu-
lated genes (right part) during disease progression, as extracted from the loadings of the genes on pc1. Expression data are given as log2 (counts per million).
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involved in ADPKD progression, the expression was normalized after
at least one drug treatment, i.e. upregulated genes were not or less
increased after treatment, or downregulated were not or less
decreased after treatment (Supplementary Table 2). Since the drug
treatments were effective in slowing disease progression, these genes
reflect the healthier state of the kidneys upon drug treatment. By
focusing on genes that respond to therapy we strengthen the involve-
ment of the genes in disease progression and as potential target to
Fig. 2. 12 distinct expression patterns are associated with PKD progression. (a) The different expression patterns observed in Pkd1cko mice representing the progression of ADPKD
towards end-stage renal disease (weeks after tamoxifen induction). For each cluster, mean log-transformed gene expression levels relative to the control mice that did not receive
tamoxifen are plotted. The top panel represents the early dysregulated clusters, the middle panel represents the clusters dysregulated in the moderate to advanced stage and the
bottom panel the clusters associated with the advanced stage of the disease. (b) Replication of expression profiles in an independent study. For each cluster, a representation factor
reflecting the gene overlap of each cluster with the expression signatures from the five different mouse groups defined in the study by Menezes et al. [15] is given in a color repre-
sentation. A representation score > 1 reflects enrichment. (c) Correlation of gene expression with disease progression. For each cluster, the average Spearman’s correlation coeffi-
cient between the expression values of the genes in a cluster and the 2KW/BW ratio was calculated. Green represents a negative correlation while red reflects a positive correlation.
Clusters that were dysregulated in an early stage have the lowest correlation with the 2KW/BW increase, suggesting they follow a different trend in disease progression. (d) Associa-
tion of cluster with drug response. A bar chart representation for each cluster showing the proportion of the 2731 genes that were also affected by one of the drug treatments: sAc-
tRIIB-Fc early (Act Early) and late (Act Late), curcumin, rapamycin short (Rapa Short) and long (Rapa Long). The x-axis represents the % of genes that were significanltly
dysregulated (P < 0.05) due to the drug treatments per cluster per drug treatment.
Fig. 3. Pathways associated with disease progression and drug response. (a) A heatmap representation of the molecular pathways significantly enriched in the different stages of PKD
(left). For each cluster category from Fig. 2A, the significantly enrichedWikipathways were obtained (FDR< 0.05) and plotted in the heatmap. Color scale reflects the representation factor
in the different phases of ADPKD (Early, Moderate and Advanced). On the right, a heatmap representation of the pathways that are enriched with significantly dysregulated genes after
drug treatment. Enrichment was established based on the representation (RF) factor calculation, where pathways that had RF>= 1 are considered significant. (b) A schematic representa-
tion of the different pathways involved in ADPKD’s progression. Pathways are selected based on theirWikipathways significance (FDR) across the different disease stages in part A.
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identify novel drugs to treat ADPKD (Figure-2D Fig. 2D). Table 1 sum-
marizes the number of genes differentially expressed in the treated
samples and involved in ADPKD progression.
3.6. Identifying drug targets from the genes associated with ADPKD
progression
To identify candidate drugs that might have a favorable effect on
ADPKD, we screened the ChEMBL database for drug-protein interac-
tions. From ChEMBL, we only used high quality drug-protein target
interactions (See Methods). This generated a list of 990 protein tar-
gets (directly assigned targets), and 356,396 interactions with
240,433 compounds. We compared these drug targets to our set of
differentially expressed genes. From the total set of 1162 genes that
were involved in ADPKD progression, 168 genes were annotated in
ChEMBL as candidate drug targets and had enough high-quality bio-
activity information to be used in our subsequent analysis (Fig. 4A).
These 168 genes were targeted by 48,050 small molecules (Supple-
mentary Table 4: Step 11).
As we were interested in the set of candidate drugs that can be
repurposed for ADPKD, we extracted compounds that were tested in
2nd, 3rd or 4th phase clinical trials. 544 out of the 48,050 compounds
met these criteria, and these compounds interacted with 111 of our
selected targets (Supplementary Table 4: Step 12). Further restriction
of the targets by including only those for which the mRNA levels
were normalized by treatment with one or more of the three differ-
ent drugs that slowed cyst formation in our preclinical models. This
resulted in a set of 63 unique candidate drug targets interacting with
339 compounds (candidate drugs) (Supplementary Table 5A). For
each candidate drug we have obtained its classification in the Ana-
tomical Therapeutic Chemical (ATC) Classification System (https://
www.who.int/medicines/regulation/medicines-safety/toolkit_atc/en/)
and removed drugs with antineoplastic classification, because theymay
show too serious side effects during long-term treatment for PKD. 32
unique targets and 116 candidate drugs passed this filtering (Supple-
mentary Table 5B). For each remaining drug-target interaction we
looked for information on the mode of action (MoA) of the drug. How-
ever, this information was only available for a small subset of these
interactions (12 targets and 23 drugs), and we filtered out the targets
that had a conflicting direction of dysregulation in relation to the its
drug MoA (3 targets were filtered out). We arrived at 29 genes that
could serve as a target for drug repurposing in ADPKD (Table 2; Supple-
mentary Table 5B).
3.7. Selection of candidate drugs
Analyzing the remaining 29 targets, we identified several that
were previously linked to ADPKD treatment. For example, Suramin
Table 1
The results of the RNA-Sequencing results of the drug treated samples (Curcumin, Rapamycin and sActRIIB-Fc). Significant genes (P-value < 0.05, t-statistics) were identified
based on the comparison of the drug treated samples to the non-treated control (see methods for details) .
PubChem CID Drug name and drug treatment
(Supplementary figure 2)
No. of genes significant genes
(P-value < 0.05, t-statistics)
Normalized no. of genes
compared to PKD progressiona
No. of genes found in PKD
progression clusters
969,516 Curcumin 8030 840 503
5,284,616 Rapamycin Short 1600 840 441
5,284,616 Rapamycin Long 1250 840 322
NA sActRIIB-Fc late-short treatment 840 840 270
NA sActRIIB-Fc early-long treatment 4200 840 365
a Number is based on the lowest maximum of significant genes. This belongs to sActRIIB-Fc Late-Short treatment.
Fig. 4. 3D-cysts assay of candidate compounds. (a) Top: Quantification of cyst size of the tested compounds normalized to forskolin induced swelling. Reference compounds rapa-
mycin (0.01 mM) and staurosporin (0.25 mM) reduce cyst size, as well as brinapant, Gamolenic Acid, icosapent and Meclofenamic Acid at highest tested concentration of 100 mM,
500 mM, 500 mM and 100 mM respectively (N = 4 wells). Bottom: Assessment of staurosporin-like induction of toxicity. Graphs representing average nuclei area, nuclei roundness
and the fraction of nuclei that are apoptotic show changes for reference compound staurosporin and for icosapent. (b)Representative images of positive and negative control and
two of the test compounds at highest tested dose; 100 mM for brinapant and 500 mM for Gamolenic Acid. Each scalebar is 400mM.
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Hexasodium a non-specific inhibitor of P2 receptors inhibiting P2Y
and P2X receptors reduced cyst growth in a 3D cysts models while a
P2 £ 7 receptor antagonist as well as gene knock-down were previ-
ously shown to inhibit cystogenesis in a zebrafish model for polycys-
tic kidney disease [36,37]. Suramin is also an antagonist of IL-6,
known to inhibit renal fibrosis in chronic kidney disease in rats [38].
Another identified drug, the PPARg agonist Rosiglitazone, was shown
to be effective in animal models for PKD [3941]. Pioglitazone, a
close PPARg agonist to Rosiglitazone, is currently undergoing clinical
trials for ADPKD [ClinicalTrials.gov Identifier: NCT02697617].
Another prioritized candidate drug was the second mitochondrial-
derived activator of caspases (SMAC)-mimetic GT13072, which
slowed down PKD progression in two Pkd1mouse models [42]. Icosa-
pent also known as ethyl eicosapentaenoic acid, another candidate
drug prioritized by our analysis, was shown to reduce PKD severity in
a mouse model, but this could not be confirmed in a small clinical
trial [43]. Additionally, three candidate drugs, the spleen tyrosine
kinase inhibitors entospletinib and R-406, and the polo-like kinase 1
inhibitor BI-2536 were previously shown to be effective in a 3D Cyst
screen of the Selleckchem library of compounds [34]. Collectively,
these previous findings support our approach in successfully identify-
ing lead compounds for ADPKD drug repurposing.
To identify new candidate drugs for the ADPKD drug development
pipeline, we evaluated six compounds in a 3D Cyst assay similar to that
performed by Booij et al. [34]. The six candidate drugs, Zileuton, Indo-
metacin, Meclofenamic Acid, Gamolenic Acid, icosapent and Birinapant
(Table 3) were selected based on additional evidence for the potential
therapeutic potential for ADPKD present in the Euretos Knowledge Plat-
form (https://www.euretos.com/) and the scientific literature.
3.8. Wet-lab validation of selected candidate drugs
To test the selected drug candidates, we grew renal epithelial cells
(mIMRFNPKD 5E4) in a 3D-gel matrix to allow cyst formation. After
96 h, cysts were co-exposed to forskolin, to induce cyst swelling, and
the selected compounds for a period of 72 h. Rapamycin, shown before
to reduce cyst swelling in several models [34,44], was used as a posi-
tive control for cyst swelling inhibition and demonstrated the
expected reduction in cyst size (Fig. 4A). Of the selected drug candi-
dates, Meclofenamic Acid, Gamolenic Acid, icosapent and Birinapant
slowed cyst growth at the highest concentration tested; 100 mM,
500 mM, 500 mM and 100 mM respectively. Zileuton and indometha-
cin, however were not as effective (Fig. 4A, top), showing no effect on
cyst size on any of the tested concentration up to 100 mM and 40 mM
respectively. Birinapant was the most potent compound, with 50%
inhibition of cyst swelling around 50mM. These results were validated
in an independent experiment (Supplementary Figure 4). To be able to
distinguish true swelling inhibiting properties from severe toxicity,
which also leads to reduced cyst size, staurosporin was included as a
prototypic toxic compound at. Looking at the effect of staurosporin at
0.25 mM on phenotypic parameters such as nucleus size and shape as
well as nucleus fractionation, there is clear induction of cytotoxicity.
Of the selected compounds however, only icosapent shows similar
kind of phenotypic changes, starting at a concentration of around
100 mM (Fig. 4A, bottom). Representative images of treatment effect
can be found in Fig. 4B. These results indicate that 3 out of 6 novel
compounds selected through our approach demonstrated to be able to
inhibit cyst swelling in vitro without apparent toxicity.
4. Discussion
In this study we combined comprehensive gene expression profil-
ing and bioinformatics, with cheminformatics to identify drugs for
repurposing and targets to further explore for ADPKD treatment. Our
approach is based on an innovative strategy that combines transcrip-
tomics sequencing of different disease states of ADPKD and drug
assays databases to arrive to a list of candidate drugs that could have
a treatment potential for PKD. Our methodology zooms-in on a set of
genes involved in ADPKD progression and proposes candidate drugs
that could alter disease progression by targeting relevant genes. Our
Table 2
The 29 drug prioritized targets grouped based on their gene category
according to MsigDB (Supplementary Table 5B).
Gene category Count of genes Genes
Protein kinases 3 CDK1
PRKCB
PRKCZ
Transcription factors 3 PPARD
STAT3
THRA
























Drugs selected for validation in 3D Cyst experiment and their results.
PubChem CID Drug name Targets (pChEMBL valuea) Results in 3D cyst assay ATC code (Level 4)
49,836,020 Birinapant BIRC2 (7.3) Effective n/a
5,280,933 Gamma-Linolenic acid (Gamolenic Acid) PPARD (6.1) Effective D11AX
446,284 Eicosapentaenoic acid (Icosapent) PPARD (5.4) Effective n/a
4037 Meclofenamic Acid AKR1C3 (6.3), AKR1C1 (5.5), AKR1C2 (5.1) Effective M01AG
60,490 Zileuton ALOX5AP (5.5) Not effective n/a




a pChEMBL is a combination of a number of roughly comparable measures of half-maximal response concentration/potency/affinity to be compared on a
negative logarithmic scale: -Log(molar IC50, XC50, EC50, AC50, Ki, Kd or Potency). We have tested compounds at 100 mM (pCHEMBL value 4). We have
selected targets for which the affinity was a pCHEMBL value > 4.0.
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work is of high relevance to PKD patients since they have limited
treatment options. Tolvaptan (Jinarc), the only treatment now avail-
able, has limited efficacy, and side-effects like massive diuresis may
limit patient adherence [20,45]. Therefore, there is a need for drugs
that specifically target the formation and growth of cysts to slow
down or halt disease progression. Given the complexity of altered
signaling in cyst-lining epithelia, a broad range of potential targets
are available, and drug-repurposing is a relative fast strategy for the
development of new treatments.
We used a tamoxifen-induced Pkd1cko mouse model to generate
expression profiles of the kidneys of 7 groups of mice with varying
levels of disease progression. Using clustering techniques, we arrived
at groups of genes that show altered expression in mild, moderate
and advanced stages of the disease, each characterized by increased
or reduced activation of certain pathways and pathogenic processes.
In the early stage, the TCA cycle, fatty acid biosynthesis, EGFR signal-
ing and G13 signaling were most significantly altered, indicating
altered metabolism, proliferation and cytoskeletal remodeling, con-
firming previous studies in PKD [15,46]. In the moderate phase, we
specifically observed increased MAPK and mTOR signaling, both
involved in a broad range of cellular processes including cell prolifer-
ation and cell stress-related pathways (MAPK) or cell growth, prolif-
eration, protein translation, autophagy, as well as actin cytoskeleton
remodeling and apoptosis (mTOR) [23,47,48]. Additionally, at this
stage we observed an up-regulation of cytokines such as IL-5 and IL-
3, corresponding to inflammatory infiltrates and an active injury
response. Inflammation and associated fibrosis became even more
prominent in the advanced phase with increased expression of mac-
rophage markers [49,50]. Furthermore, in the late-phase we see evi-
dence of severe cell damage and tissue injury response with the up-
regulation of pathways involved in oxidative stress, DNA damage
response, and P53 signaling [29,51].
To arrive to a set of candidate drugs that could be repurposed for
ADPKD, we took advantage of ChEMBL, where we identified mole-
cules that target genes of the ADPKD progression profile. The advan-
tage of using ChEMBL is that it is based on primary scientific
literature, allowing us to validate the source of the bioactivity when
needed. However, it should be noted that a similar approach could be
envisioned with PubChem Bioassay or another source of biological
activities. To make sure that the drug target relationships are of high
quality we followed a series of filtering steps that led to 116 mole-
cules binding to 29 genes. It is known that on average approved drugs
show activity for 6 protein targets, so our selected molecules cannot
be considered more promiscuous than normal in particular given
that they have gone through phase 1 clinical trials [52]. Our filtering
steps aim to minimize the number of ‘wet-lab’ experiments by focus-
ing on only the most relevant and most confident information from
literature. To be able to repurpose approved drugs, we did not only
retrieve bioactivity data but also retrieved the primary (mode of
action) target of each drug. Hence, we also included associated gene
targets for approved drug that do not directly relate to the working
mechanism described in the literature. As we included only drugs
that are used in phases 2, 3 or 4 clinical trials and then filtered out
drugs that have antineoplastic effects, we aimed to optimize our
selection of drug repurposing candidates. The rationale being that
compounds showing toxicity effects in phase 1 drugs known to kill
(tumor) cells are less suitable for chronic administration to ADPKD
patients. Out of the 116 candidate drugs that we prioritized for
ADPKD treatment, we identified 5 molecules that were previously
linked to PKD in 3D cultures and/or preclinical studies. More research
is required to decide for further clinical development of these drugs/
drug targets. Using a 3D-cyst drug screen assay, we have tested the
effect of a further 6 drugs on cyst size at four or five dosages. In all
cases the screening concentration we used was higher than the noted
pChEMBL value (indicating that more than 50% of the compound was
bound to the targets). 4 out of the 6 tested drugs had a positive
impact on cyst size (decreased cyst size compared to controls). This
became more evident at the high dosage, which might suggest a cer-
tain toxic effect on the cyst. We further analyzed the toxicological
effects of these drugs and our initial toxicology analysis, revealed
toxic effects of only 1 of the tested drugs.
The three remaining effective and nontoxic compounds are
Meclofenamic Acid, Gamolenic Acid and Birinapant. From Table 3 it
follows that the following targets could be responsible for the
observed activity of these three compounds: BIRC2, PPARD, and
AKR1C1. BIRC2 is the only known target for Birinapant and is in the
identified targets. PPARD is a target for both Gamolenic Acid and Ico-
sapent (and in the list of identified targets). AKR1C1, AKR1C2, and
AKR1C3 are all in the list of identified targets and have an affinity for
the active Meclofenamic Acid. However, the inactive compound Indo-
metacin also has an affinity for AKR1C2 and AKR1C3, ruling them out
as the prime targets for Meclofenamic Acid. Finally, PTGES and
ALOX5AP seem not to be relevant targets as the inactive compounds
Indometacin and Zileuton have affinity for them. It should be noted
that the here retrieved targets represent only the targets for which
activity was measured in the scientific literature; absence of these
measurements does not demonstrate the absence of potential affin-
ity. Moreover, the tested compounds may also have more targets on
which they may demonstrate affinity (Supplementary Table 6). How-
ever, we selected in our approach only genes that were shown to be
affected in ADPKD, which is not true for the other targets listed in
Supplementary Table 6.
For the identified drugs we were also able to obtain more relevant
information from literature, interestingly all these results are in line
with our findings from Table 3. Meclofenamic Acid has been identi-
fied to target aldo-keto reductase family 1, which is implicated in ste-
roid metabolism [53], which was reported to be involved in cyst
development in cpk rat, a PKD model [54]. Gamolenic Acid has been
selected based on PPARd, which controls an array of metabolic genes
involved in glucose homeostasis and fatty acid synthesis/storage,
mobilization and catabolism. For other PPAR family members, PPARa
and PPARg , are being studied in (pre)clinical trials for PKD [40,55].
Birinapant is a SMAC mimetic and known modulator of apoptosis,
which binds to and inhibits the activity of Inhibitors of Apoptosis Pro-
teins (IAPs), including BIRC2(=cIAP1) thereby freeing caspases to acti-
vate apoptosis [56]. Another SMAC mimetic, GT13072, was
previously shown to slow down PKD progression in Pkd1 mouse
models [42]. Overall, these drug candidates are relevant to the molec-
ular events involved in ADPKD progression. However, further testing
and pre-clinical experiments are needed to determine the efficacy of
these drugs for ADPKD treatment.
To our knowledge this is the first drug repurposing effort in
ADPKD at this scale. It expands on the previous transcriptomics
efforts performed by others in the field. In this study we used deep
RNA-sequencing of ADPKD transcriptomics across multiple disease
stages, rather than microarrays [15,29,57,58]. The aforementioned
studies differ in several elements, most notably their source of stud-
ied samples. Where we and Menezes et al. used adult Pkd1 mutant
mice, Pandey et al. used embryonic kidneys of Pkd1 mutants and
both Song et al. and de Almedia et al. used patient obtained ADPKD
kidneys of ADPKD patients. Despite these differences, comparable
dysregulated pathways have been reported. In all studies, abnormali-
ties in metabolism, cell cycle and cell death are observed. Our results
suggest that irregulates in metabolism and cell growth could play a
role in early cyst development. Furthermore, we sequenced drug-
induced ADPKD models to target progression involved genes at a
higher precision, and thus enabling enhanced drug-repurposing. Our
method screens thousands of approved drugs for their potential to
treat ADPKD, expanding the work of others that focused on studying
a selected number of drugs [5963].
Although our approach is supported by wet-lab and in silico
experiments, we acknowledge several limitations of our study. (1).
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For the adult onset PKD mice, we only included males, while several
results suggest ADPKD presentation differences between males and
females [64]. Despite the differences in progression rates, gene net-
work analyses revealed that the underlying mechanisms of PKD pro-
gression between male and female mice do not differ [15]; (2) Our
starting point was gene expression data, while not all molecular pro-
cesses act through changes in gene expression. Stage specific proteo-
mics data and analysis of posttranslational modifications would be
needed to obtain a more comprehensive insight in the molecular
pathways associated with disease progression and would improve
the quality of our drug predictions; (3) Drugs and their targets are
biased towards the most studied drugs, diseases, and proteins (i.e.
enzymes and G protein coupled receptors make up more than 75% of
the data), while less-well characterized drugs may constitute equally
good candidates for drug repurposing strategies [65]; (4) Further
functional wet-lab experiments would be needed to determine the
exact contribution of each gene to ADPKD progression and cyst
growth. As more data will be implemented in ChEMBL and other bio-
medical database in the future, the power of this approach will
increase. In addition, this approach is widely applicable to other dis-
eases as well, provided that large scale high quality transcriptomic/
proteomics data is available to be compared to databases cataloging
drug affinity and activity towards a broad range of protein targets.
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Abstract. Given the significant time and financial costs of developing a commercial drug, it 
remains important to constantly reform the drug discovery pipeline with novel technologies 
that can narrow the candidates down to the most promising lead compounds for clinical 
testing. Computational approaches are used to expedite the drug discovery processes. 
Semantic knowledge graphs can assist these computational approaches, because they 
connect different biological databases and reflect the relationships between genes, pathways 
and diseases. Here, we took advantage of the Euretos Knowledge Platform (EKP), a 
commercial database that integrates more than 170 different biological resources including 
DrugBank, and evaluated the usefulness of the underlying semantic knowledge graphs to 
predict novel drug-disease associations. As a positive set, we extracted 403 drug-disease 
associations from an independent resource, Metab2MeSH. An equally sized negative set was 
created by reshuffling of these drug-disease triples. For prediction of new associations, it is 
important to assess which paths in the knowledge graph optimally represent novel drug-
disease associations. All 403 drug-disease associations in the positive and negative dataset 
were connected by at least one intermediate concept from 12 out of the 14 semantic types 
available in EKP.  ‘Chemicals & Drugs’ was the most informative intermediate semantic type 
and distinguished the positive and negative sets best (Kolmogorov-Smirnov p-value: 7.4. 10-
23). Also graph network features such as the total number of intermediate concepts (count), 
the number of different semantic categories (diversity), and the predicates connecting a drug-
disease pair were successful in separating the positive from the negative sets. These features 
can be used to build a classifier for the prediction of novel drug-disease associations from the 
Euretos Knowledge Platform facilitating drug repurposing in preclinical research.  
Keywords: Drug repurposing, drug discovery, Semantic graphs, network mining, 
machine learning.  
Introduction 
In silico methodologies are becoming more important in the modern-day drug discovery 
pipeline. Computational drug discovery techniques accelerated the identification of drug 
targets and significantly contributed to the different stages of drug development [1]. Most 
efforts are concentrated into developing methods for the prediction of drug target 
interactions that mitigate the expensive costs of experimental drug development and 
optimization [2]. Moreover, these methods are allowing for drug repurposing efforts that 
identify new therapeutic applications for existing drugs and reduce research cost and time 
due to the existing extensive clinical studies [2, 3].   
Given that the majority of diseases cannot be explained by single-gene defects but by the 
coordinated functions of their complex gene networks, drug development needs to shift its 
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attention towards understanding network-based perspectives of disease mechanisms. 
Network-based approaches are providing important insights into the relationship between 
drugs and diseases. An investigation into the interaction between drug targets and 
disease genes revealed that they are not closely related [4]. Additionally, network-based 
approaches are showing promise in predicting novel targets and new uses for existing 
drugs [5].  Current network-based approaches rely on drug target profile similarities. 
These similarities are defined by either the number of targets two drugs share or the 
shortest paths between their interactomes. However, these studies focus only on using a 
limited number of databases related to protein drug targets, leaving a large amount of rich 
data untapped.  
Semantic and text-mining approaches that screen hundreds of thousands of published 
literature articles have demonstrated the possibility of extracting concepts of biological 
meaning of various types. Semantic knowledge graphs are constructed to connect 
concepts of various types based utilizing a number of resources such as literature 
knowledge and biological databases. Such knowledge graphs can then be used to infer 
novel connections based on network mining methods [6, 7]. In addition to semantic 
connections, large efforts were made to integrate biological databases across gene, 
protein, pathway, disease and drug domains. The Euretos Knowledge Platform (EKP, 
http://www.euretos.com/) is a commercial database that integrates more than 170 
different biological resources including semantic data [http://www.euretos.com/files/- 
EKPSources2017.pdf]. These data sources are used by EKP to build a large network of 
connected biological concepts. Disease and drug concepts in EKP are directly or 
indirectly connected based on prior knowledge found in publications and/or other 
databases. We expect that leveraging a large set of databases will enhance our drug 
discovery ability and avoid relying on a single source of information to associate drugs to 
diseases. Each semantic type provides us with an additional layer of information that can 
be exploited to identify novel drug disease associations.  
In this work, we have taken advantage of the EKP to evaluate the usefulness of the 
underlying semantic knowledge graphs to predict novel drug-disease associations. With 
the current exponential growth in biological data, semantic knowledge graphs have a 
great potential for drug discovery.  
Materials and Methods  
Data Acquisition and Mapping in EKP 
 Drug disease pairs were acquired from Guney et al [8]. We specifically acquired the drug 
disease associations based on their analysis. We had 403 pairs of 239 drugs and 78 
diseases that formed our positive “gold-standard” (GD) data. Randomly shuffling the 
positive dataset, we created 20 negative random datasets and used their average in the 
downstream analysis.  
In EKP we first mapped the DrugBank IDs of the drugs in our datasets to drug concepts in 
EKP. We used full disease names to map the diseases in our dataset to disease concepts 
in EKP. Triples of drug disease pairs were identified in EKP if they were directly 
connected by at least one of the resources used in EKP (Figure-1). Predicates of drug 
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disease triples were classified as “relevant” if they belonged to one of the following 
categories: “treats”, “affects”, “prevents”, “disrupts”. The LUMC has a local installation of 
this knowledge graph for research purposes  
Network Features 
Network features were calculated for the intermediate concepts connecting drug disease 
pair. To evaluate if we could use the indirect associations to predict novel associations 
between drugs and diseases, we used the positive and negative datasets as follows. For 
each indirect association, we calculated a number of features and tested if these features 
could separate the two datasets. These features were calculated for each semantic 
subcategory (SubSemantic) available in EKP.  
I. Count_normalized referred to as count in the following text:
   (“SubSemantic_typeY”) = X ÷ (y × z)          (1) 
X = total number of SubSemantic_typeY connecting the drug (y number of unique drugs 
making one drug concept) with disease (z number of unique diseases making one 
disease concept)  
II. Diversity = The total number of unique SubSemantic categories connecting the drug
and disease concepts per semantic type.
III. Predicates from the drug concept to the intermediate concept and from the in-
termediate concept to the disease concept were combined and referred to as “predicate
path”. We used the Chi-square test to identify, within each semantic subcategory, the most
enriched paths in the GD vs the negative dataset (cutoff p-value < 0.05). We filtered out
paths that made up less than 1% of the total amount of paths within each semantic
subcategory.
For I and II we used the Kolmogorov–Smirnov to test the similarity of the distribution of 
scores between the positive and the negative datasets (cutoff p-value < 0.05)  
Results and Discussion  
Concept Mapping and Direct Associations 
We acquired the dataset of curated drug disease relationships (drugs used in the 
treatment of certain diseases) from Guney et al [8]. The GD dataset included 239 drugs, 
78 diseases and 403 drug-disease pairs. For the negative dataset, we reshuffled the GD 
into 20 random datasets. The results of the negative datasets were averaged and 
compared to the GD.   
 We used DrugBank IDs available in the GD dataset to map drugs from the GD and 
negative datasets into EKP concepts and we used the full disease name to map 
diseases, since no unique identifier was supplied in the GD dataset. Out of 239 drugs, 
79
Drug Repurposing Using a Semantic Knowledge Graph 
235 were mapped successfully. All diseases were mapped successfully into EKP. 
Whendisease or drug term mapped to more than one concept in the EKP, this was 
corrected for  (Figure-1).   
 Using the EKP we retrieved the triples for drug-disease pairs found in the GD and 
negative datasets. Each semantic triple consists of a subject-predicate-object, where the 
subject and the object refer to the drug and the disease respectively, and the predicate 
refers to the relationship connecting them. From the pairs found in the GD, 83% mapped 
to a triple in the EKP, whereas in the negative datasets 22% of the pairs mapped to a 
triple in the EKP.  Moreover, from the mapped triples in the GD, 90% had a predicate type 
that we consider positive for a drug-disease association i.e. ‘treats’, compared to 75% in 
the negative datasets. These results demonstrate that the drug disease pairs in the GD 
and the negative datasets are different in two main aspects. 1). Most of the GD drug 
disease pairs could be represented in direct triples owing to prior knowledge of the pair’s 
relationship. 2). The type of the predicates is different when comparing the triples of the 
GD and negative datasets, where the GD contains a higher proportion of the “relevant” 
predicates.  
Evaluating the Indirect Drug-Disease Associations 
As we are interested in drug repurposing, we were looking for novel associations between 
drugs and diseases. We utilized the indirect drug disease associations as a basis for our 
method, where we aim to mine the full EKP graph of indirect drug disease associations 
for strong candidates using network based features. To identify which features are useful, 
we used the GD and the negative datasets and evaluated several network features on the 
indirect associations retrieved from them. In the EKP, 14 semantic types are defined 
based on the semantic groups as defined by the Unified Medical Language System [9], 
with a number of semantic subcategories under each semantic type. Our analysis of 
indirect associations, i.e. drugs and diseases that connected via a third concept, was 
done per subsemantic category.  
All 403 drug-disease associations in the GD and negative dataset were connected by at 
least one intermediate concept from the semantic types available in EKP. Out of the 14 
possible semantic categories, 12 were found to connect a drug and a disease. We next 
evaluated which semantic and semantic subcategories were the most informative. Using 
the count diversity feature, defined as the total number of a certain intermediate concept 
connecting a drug disease pair, the semantic type ‘Chemicals & Drugs’ was the most 
informative intermediate semantic type and distinguished the positive and negative sets 
best (Kolmogorov-Smirnov p-value: 7.4. 10-23). Density plots of the count values per 
semantic and semantic subcategory in both the GD and the negative data reveal visually 
that the GD contained a higher number of indirect concepts in most semantic categories 
compared to the negative dataset, such as “Chemicals & Drugs”, “Anatomy”, “Disorders” 
and “Procedures” semantic categories (Figure-2A, Table-1).  
Another feature we investigated was the diversity of the different semantic types 
connecting a drug disease pair. In this analysis we compared the total number of unique 
semantic categories and semantic subcategories in the drug disease pairs of the GD and 
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negative datasets. As observed for the count feature, the GD drug disease pairs 
displayed a higher semantic diversity in their intermediate concepts (Figure-2B). 
We also investigated the predicate types that connect the indirect concept with the drug 
disease pairs. In this analysis we used two predicates, the one connecting the drug with 
the intermediate concept and the one connecting the intermediate concept with the 
disease concept. The combination of these two predicates in this order is referred to as 
the predicate path. Using the chi-squares test we investigated if there were predicate 
paths that are enriched in the GD and negative datasets. We found the most enriched 
paths in the “Amino Acid, Peptide or Protein” and “Pharmacologic Substance” semantic 
subcategories (Figure-2C). For example,, the path “drug is compared with  
Pharmacologic Substance  treats Disease” that belongs to the “Pharmacologic 
Substance” semantic subcategory is strongly enriched in the GD that can be interpreted 
as drugs that are known to be similar in function or chemical properties can be 
repurposed for the same disease.   
These results indicate that the type of, count and the predicates relating to the 
intermediate concepts connecting a drug and a disease pair were informative in 
differentiating positive and negative datasets. The added values of using a diverse set of 
semantic categories was demonstrated. In the count feature, we found almost all 
semantic categories shifted towards higher values in the GD when compared to the 
negative data. Additionally, the diversity feature revealed that the GD tends to have a 
higher number of semantic categories and subcategories as intermediate concepts 
connecting drugs and diseases. Having the ‘Chemicals & Drugs’ as the most 
differentiating semantic category also demonstrates the importance of looking at drug 
properties and not completely relying on the drug targets.   
In contrast to other tools, our methodology is different in a number of ways. The quantity 
and diversity of databases that we included is larger and the content much richer than 
other comparable tools. In terms of quantity we have taken advantage of EKP that 
integrates more than 170 resources. Other network-based tools such as SLAP [6] and 
ProphNet [10] include 17 and 3 databases respectively. In terms of diversity, EKP 
includes databases that span drug, disease, phenotype, protein, gene and molecular 
pathways. Additionally, EKP takes advantage of mining the PubMed published literature. 
To our knowledge this is the most resource inclusive effort in network-based drug disease 
associations. Our methodology utilizes drug disease connections beyond the commonly 
used drug-targets-disease framework to expand the possibilities to include other semantic 
categories, such as drug-drug and disease-disease similarities, phenotypes, pathways, 
proteins and biological function annotations.   
Conclusions 
Computational efforts in drug discovery are gaining popularity for their ability to reduce 
the costs involved in drug development. Network-based approaches are currently being 
used for drug repurposing efforts. We have taken advantage of the EKP that integrates 
more than 170 biological sources. Leveraging 12 semantic categories that are found in 
the EKP to connect drug and disease pairs, we identified three main network features that 
showed significant differences in the characteristics of the intermediate concepts 
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connecting the drug disease pairs in the Gold Standard and negative datasets. These 
features can be readily used to build a classifier that will mine the full EKP graph to 
propose novel drug disease associations. Additional network features that are tailored to 
specific semantic types can be further extracted to fine tune the performance of the 
classifier.  
This work demonstrates that semantic knowledge graphs have a strong potential in 
mitigating drug discovery efforts. We expect semantic graphs to grow with the exponential 
growth in data generation in life sciences. Thus, rendering semantic knowledge graphs 
even more valuable for drug discovery.  
Table 1. Top 5 most significant semantic subcategories based on count feature. 
Semantic type(subcategory)   Semantic Subcategory   Kolmogorov-Smirnov p-value 
Organic Chemical  Chemicals & Drugs 7.39E-23 
Pharmacologic Substance Chemicals & Drugs 1.09E-22
Indicator, Reagent, or Diagnostic Ai 
Chemicals & Drugs 7.12E-19 
Hazardous or Poisonous Sub- 
Fig. 1. We have used the Euretos Knowledge Platform (EKP) as the semantic knowledge graph in this 
analysis. Biological concepts (e.g. drugs, diseases, genes) are represented as circles, with different colors 
suggesting the variety of semantic types in the EKP (A). The drug disease pairs we acquired from an 
independent source were mapped to EKP concepts (B). Notably, mapped pairs were connected by 
intermediate concepts of 12 out of 14 different semantic types. We extracted network features from the 
intermediate concepts (C) to use them in building a classifier (future work) (D) to predict novel drug disease 
associations in the semantic network (E). Black dashed line reflects ongoing parts D and E of which their 
results are not yet included in this manuscript.  
stance Chemicals & Drugs 1.2 E - 16  
Chemical Viewed Structurally Chemicals & Drugs 2.72 E - 16  
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Fig. 2. A). Density plots of the count feature of three semantic subcategories. The higher the count value on 
the x-axis the higher the higher this semantic subcategory is found as an intermediate concept between drug 
and disease pairs. B). Boxplots representing the diversity feature for concepts in each of the 12 semantic 
categories. For each semantic category, we have calculated the presence of each of the subcategories 
belonging to that semantic category. C). Word Cloud representation of predicate paths of the 
“Pharmacological Substance” semantic category. P-values of the chi-square test residuals were used as an 
input to the cloud to calculate the enrichment of each path in either the positive and the negative datasets.  
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1. Introduction to molecular signatures
In recent years, new high-throughput measurement technologies for biomolecules such as 
DNA, RNA, and proteins have enabled unprecedented views of biological systems at the 
molecular level. Molecular signatures are based on omics data, made of a single or multiple 
data types (genome, transcriptome, proteome, and metabolome data) used to identify 
biological signals. Molecular signatures could be used to predict a phenotype of clinical 
interest such as a cancerous or diabetic state, molecules not previously known to be 
involved in the underlying molecular pathology, or molecular response to therapeutic drugs 
and their physiological toxicity. In this thesis, we used transcriptomic signatures to discover 
the molecular events that lead to the formation of cysts in autosomal dominant polycystic 
kidney disease and promote novel drug candidates for its treatment. There are countless 
examples of successful use of molecular signatures in disease study and drug discovery. 
For instance, the work of Angus et al demonstrates the application of whole-genome 
sequencing to identify mutational signatures linked to different types of chemotherapy 
pretreatments for breast cancer1, thus providing useful genomic insights that could be 
leveraged to improve the future of patient management. 
2. Robustness of molecular signatures and use in disease study
Despite their wide use, molecular signatures’ success is hindered by limited reproducibility 
and variable performance on independent test sets2, which in a large part could be attributed 
to the low signal-to-noise ratio inherent to omics datasets, the prevalence of batch effects in 
omics data, and molecular heterogeneity between samples and within populations3. The 
noise could be due to errors that are technical in nature (uncontrollable variation in different 
instrument readings collected from the same sample) or biological in nature (uncontrollable 
variation in different samples collected from the same biological condition). An event may 
also be considered part of noise even if it is biological and reproducible, simply because it 
encodes aspects of phenotype irrelevant to the current study. These issues are exacerbated 
by the fact that the datasets used to develop molecular signatures tend to have small sample 
sizes relative to the number of molecular measurements4,5.  To overcome these limitations, 
experimentalists are deploying several strategies to enhance true biological signal detection. 
Meta-analysis of experimental data is an example of these methods. This approach 
combines the molecular signature of single studies into a uniform dataset that greatly 
eliminates single study anomalies and enables the identification of a refined molecular 
signature that limits the influence of experimental design, choice of the disease model, 
analysis methods, etc. on the biological signal. For instance, in chapter-2 of this thesis, we 
combined four ADPKD expression profiling studies by focusing on genes that are 
significantly dysregulated in two or more studies, which led to the identification of the PKD 
Signature, a set of 1,515 genes that are commonly dysregulated in PKD studies. Our work 
revealed that genes that appear consistently dysregulated in multiple studies are significantly 
more enriched when tested against an independent relevant study, and are less prone to 
experimental differences. We also combined 7 renal injury-induced studies to eliminate noise 
and identify genes implicated in renal injury repair and involved in ADPKD pathology. 
Another method to eliminate noise in biological data relies on filtering biological events using 
prior knowledge. Prior knowledge could be stored in biological databases such as pathway 
annotation databases (e.g., KEGG), or stored in public literature (e.g., PubMed). In chapter-
89
Discussion
2, we used several databases like KEGG, MSigDB and DAVID to validate the identified 
ADPKD signature, by measuring the enrichment of ADPKD associated pathway genes (e.g., 
proliferation, apoptosis, immune response, cell cycle) in the ADPKD signature and 
established that the ADPKD signature had twice the enrichment for ADPKD associated 
pathway genes compared to signatures derived from single studies. We applied a similar 
approach in chapter-3, where we used prior annotation of transcription factors (TFs) in 
MSigDB6 to identify TFs associated with ADPKD (e.g., STAT3, and RUNX1) on the basis of 
their dysregulation in the ADPKD signature. Furthermore, we demonstrated the utility of 
leveraging public literature to filter noise and enhance true biological signals by mining 
scientific knowledge from PubMed abstracts7 in the identification of injury-repair-associated 
genes in PKD in chapter-2. Using this method, we identified 237 injury repair-associated 
genes from the literature to supplement the injury profile we identified from expression data. 
A third technique used by scientists to enhance signal-to-noise ratio relies on integrating 
complementary layers of data. For instance, scientists combine genomics and 
transcriptomics, to gain insights into the expression patterns of genes with somatic 
mutations. This method is extremely helpful in understanding the molecular events 
contributing to cancerous states. In addition, combining transcriptomics and proteomics data 
has been shown to improve disease study and drug development8-10. This is demonstrated 
by the efforts of Varemo et al that integrated transcriptomics and proteomics data to 
reconstruct the Human Myocyte Metabolic Network for the identification of Diabetes 
Markers11. Other forms of molecular data were also combined, for instance, transcriptomics 
and metabolomics12, proteomics and metabolomics13 and Chromatin immunoprecipitation 
with DNA sequencing (ChIP-Seq)14. In chapter-3, we identified STAT3 and RUNX1 as TFs 
with altered expression in the PKD Signature, and combining transcriptomics data with ChIP-
Seq data we identified several key target protein for these TFs; STAT3 (Scp2, Kif22 and 
Socs3) and RUNX1 (Bcl3, Tnfrsf12a) which could be further investigated for their role in 
PKD development. 
3. Molecular signatures for drug repurposing and discovery
In silico drug discovery methods can be classified into three types. The first is based on 
transcriptional molecular signatures, which measure genome-wide transcriptional 
perturbations of a biological system after drug induction, leading to the identification of the 
signature of the compounds’ activity on biological systems. These molecular transcriptional 
signatures can then be compared to establish therapeutic relationships between known 
drugs and new disease indications. In chapter-4 for instance, we have first identified the 
ADPKD disease progression profile by sequencing the transcriptome of Pkd1cko mice with 
varying disease severity (mild, moderate, and advanced). Furthermore, we identified 
significantly dysregulated genes in Pkd1cko mice treated with drugs proven to reduce cyst 
size and slow ADPKD progression in murine (Rapamycin (Sirolimus), Curcumin, and soluble 
activin receptor IIB Fc (sActRIIB-Fc)). Combining the ADPKD progression profile genes with 
the genes altered in the drug-treated mice, we identified genes that could potentially be 
targeted to modulate ADPKD progression. Although the approach we followed would not 
identify the molecular aspects of the drugs’ cyst reducing mechanism, it allowed us to 
identify the transcriptome of the milder forms of ADPKD and consequently the genes that are 
implicated with ADPKD’s progression.  However, the exact role of these differentially 
expressed genes in ADPKD progression is difficult to predict. Further analysis of these 
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genes via the ChEMBL database led to the identification of 116 drug candidates targeting 29 
proteins, of which several were previously linked to renal disease such as Rosiglitazone15. 
One of the most comprehensive and systematic approaches leveraging this approach is the 
LINCS database, previously known as the Connectivity Map project16. Initially, the LINCS 
database contained profiles of 164 drugs and currently has a library containing over 1.5M 
gene expression profiles from ~5,000 small-molecule compounds, and ~3,000 genetic 
reagents, tested in multiple cell types. These signatures then form the basis of comparing 
drugs' mechanism of action at the transcriptional level.   
The second class of methods is network-based that aims at organizing the relationships 
among biological molecules in the form of networks to find newly emerged properties at a 
network level, and to investigate how cellular systems induce different biological phenotypes 
under different conditions. A network can be depicted as a connected graph, where each 
node can represent either an individual molecular entity (e.g., a drug), its biological target, a 
modifier molecule within a biological process, or a target pathway, while an edge represents 
either a direct or indirect interaction between two connected nodes. By applying novel 
algorithms on these networks, novel associations between drugs and diseases, and drugs 
and protein targets could be derived allowing for the discovery of novel drug candidates to 
treat various diseases. In chapter-5, we analyzed semantic knowledge graphs, a subclass 
of knowledge networks that include data mined from literature, to demonstrate the utility of 
network-based approaches in identifying drug-disease with potential clinical efficacy. Our 
results revealed that the extracted network-features such as the total number of intermediate 
concepts (count), the number of different semantic categories (diversity), and the predicates 
connecting a drug-disease pair were successful in separating the positive from the negative 
sets. The positive dataset included 239 drugs, 78 diseases, and 403 drug-disease pairs17 
and their drug-disease interactions were analyzed within the Euretos Knowledge Platform, a 
commercial knowledge graph that semantically integrates 200 biomedical knowledge 
sources. This work demonstrates that semantic knowledge graphs have a strong potential in 
mitigating drug discovery efforts. 
The third class of methods is ligand-based and assumes similar compounds tend to have 
similar biological properties, and similarity between representations is used to assess 
whether a compound modulates the activity of a target or treats a disease like a known 
drug18.  Such methods make use of large-scale virtual screening experiments that analyze 
molecular shape or molecular docking data to suggest possible further development of hits 
into lead19,20. These methods are becoming more feasible given the drastic growth in public 
databases, such as PubChem, ChEMBL, and DrugBank, which store a large amount of 
chemical/biological information such as cellular activity, binding activity, and functional 
data21-23. For instance, in chapter-4 we screened the ChEMBL database for all clinically 
tested drugs (only drugs tested in phases 2, 3, or 4 of clinical trials) that target the proteins 
we identified as part of the ADPKD progression profile. As we anticipate that ADPKD 
treatment will be administered in the long-term and to limit drugs that might cause serious 
side effects, we filtered all drugs with antineoplastic classification based on the Anatomical 
Therapeutic Chemical (ATC) Classification System. In addition to the basic aforementioned 
methods, a new set of methods that utilize machine learning are gaining popularity, 
especially relevant for identifying disease-drug associations. For instance, Zhang et al 
introduced a matrix factorization method that combines bioactivity data with disease 
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information, in one framework to identify new drug candidates based on drug similarity and 
disease similarity24.  
Additionally, computational tools are increasingly being leveraged to predict drug-target 
interactions to narrow down the scope of the search of candidate medications 25. The 
majority of these methods rely on the knowledge of the three-dimensional structure of the 
biomolecular target to estimate the affinity of ligands to a target protein with considerable 
accuracy and efficiency, however, the availability of 3D protein structures remains a 
significant bottleneck26.  
4. Future outlook, exciting developments, and key challenges in
drug discovery
Drug discovery and development is a time-consuming and extremely expensive 
process. It is estimated that the research and development cost for one molecular 
entity is approximately USD 2.7 billion27. In recent years, the drug discovery process 
has benefited from the latest technological developments in biomedicine. In 
particular, the increased availability of high-throughput omics technologies resulted 
in a wealth of biological data that we are only starting to tap into. Data availability has 
drastically increased with the decline in sequencing costs, enabling higher data 
resolution (e.g., single cells or subcellular localizations). For instance, Single-cell 
transcriptome profiling (scRNA-seq) has enabled high-resolution mapping of cellular 
heterogeneity, development, and activation states in diverse systems, furthering our 
understanding of disease pathogenesis28,29. We are also witnessing an increase in 
the type of molecular data available to study diseases enabling a systems-view into 
disease etiology across DNA, RNAs, and proteins. For instance, cis-regulatory 
elements and non-coding RNAs are shown to play an important role in disease 
development30,31. The phenome is another source of data that is exploited recently 
for drug discovery, and phenome-wide association studies (PheWAS) are gaining 
popularity as a systematic approach to statistically estimate the association between 
single-nucleotide polymorphisms and a large number of different phenotypes32. The 
work of Denny et al demonstrated the viability of PheWAS (based on EMRs) in 
detecting novel associations between genetic markers and human diseases33.  
In addition to the growth in data diversity and availability, there are major 
developments in experimental technologies to study diseases and accelerate drug 
discovery. A key example is the use of CRISPR/Cas9-based methods to perform 
combinatorial screens effectively in cells and develop therapeutics. In drug 
discovery, CRISPR/Cas9 allows us to perform genome-wide screening by 
systematically inactivating, or knocking out, the ~20,000 protein-coding genes found 
in humans to discover which proteins should be targeted for a disease treatment34,35. 
CRISPR/Cas9 could also be used in therapeutic applications by allowing scientists to 
target the underlying cause of disease and possibly cure it by modifying the patient’s 
genome36,37. Organoids (3-D culture systems) are another technology expected to 
develop into a powerful tool for drug discovery. Organoids are based on ex vivo 
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biopsy samples from patients or animal models used for drug testing, gene editing, 
or research on prognosis. Organoids could be used to mimic animal or human tissue 
in a dish, from its early development to its organogenesis or adult stage. For 
instance, growing human-derived tissues ex vivo has opened the possibility to study 
human development, to model human disease directly from individual patients, or to 
test therapeutic compounds in a personalized medicine approach 38. In fact, in 
chapter-4 we used cyst-like organoids derived from Pkd1-KO mouse-inner 
medullary collecting duct (mIMCD3) cells to test the impact of computationally 
prioritized drug candidates on cysts formation.  
Although these technologies provide immense hope for biomedical research, several 
challenges need to be tackled. The increase in data resolution and data types 
increases the complexity of integrating them and requires the use of automated 
methods to process large datasets rapidly and robustly, and then accurate models to 
identify meaningful insights such as drivers of gene expression patterns in time and 
across organs upon perturbation. Furthermore, data security, sharing, and ownership 
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In de afgelopen 20 jaar zijn de medische wetenschappen getuige geweest van belangrijke 
resultaten die werden gekenmerkt door de voltooiing van het menselijk genoomproject in 
2003. Vanaf dat moment daalden de kosten van DNA-sequentiebepaling aanzienlijk en dit 
markeerde vervolgens de komst van het data-tijdperk in de medische wetenschappen. In dit 
proefschrift hebben we me gericht op het onderzoeken van de voordelen van big data bij de 
behandeling van ziekten bij de mens, en specifiek op het onderzoeken van nieuwe 
behandelingen voor autosomaal dominante polycysteuze nierziekte (ADPKD). ADPKD is een 
ziekte die de nieren van de patiënt aantast en kenmerkt zich door met vloeistof gevulde 
cysten die zich in beide nieren vormen. ADPKD heeft momenteel zeer beperkte 
behandelingsopties; patiënten kunnen nierfalen ontwikkelen en hebben uiteindelijk vaak een 
niertransplantatie nodig. In hoofdstuk 2 van dit proefschrift zijn we begonnen met het 
combineren van de verschillende openbaar beschikbare expressieprofielen van ADPKD om 
te komen tot een  uniform ADPKD-genexpressie profiel. Expressieprofielen worden gemaakt 
door de volledige set RNA-transcripten (tot expressie gebrachte genen) onder specifieke 
omstandigheden of in een specifieke cel vast te leggen - met behulp van high-throughput 
sequencing-methoden. Het hebben van een uniforme expressieprofiel vergroot ons begrip 
van de genen die bij de ziekte betrokken zijn en minimaliseert fouten die zouden kunnen 
voortkomen uit het gebruik van verschillende technologieën of verschillende diermodellen. 
Enkele experimenten zijn beperkt tot een specifieke technologie, diermodel en / of 
ziektetoestand. Het is waardevol om verschillende onderzoeken te combineren om deze 
beperkingen te overwinnen. In ons werk hebben we aangetoond dat het combineren van 
experimenten met verschillende ziektemodellen en sequentie technologieën een sterker 
expressieprofiel creëert met een grotere percentage van genen die betrokken zijn bij de 
ziekte. Verder hebben we in hoofdstuk 3 deze expressie-signatuur gebruikt om een klasse 
van genen genaamd transcriptiefactoren (TF's) en hun rol in ADPKD te bestuderen. 
Transcriptiefactoren zijn bijzonder interessant omdat ze in staat zijn de expressieniveaus van 
andere genen te reguleren. Het zijn daarmee belangrijke organisatoren van moleculaire 
gebeurtenissen die aanleiding kunnen geven tot de ontwikkeling van cysten bij ADPKD-
patiënten. In hoofdstuk 3 ontdekten we twee TF's, STAT3 en RUNX1, die verder onderzocht 
zouden kunnen worden op hun rol in cystenvorming. We hebben ook een paar andere genen 
belicht die door deze twee TF's worden gereguleerd en als een mogelijk aangrijpingspunt 
kunnen dienen voor medicijnen voor ADPKD-patiënten. In hoofdstukken 2 en 3 
combineerden we grote hoeveelheden transcriptomics-gegevens, mogelijk gemaakt door 
aanzienlijke vooruitgang in DNA-sequentie technologieën. 
Verder hebben we in hoofdstuk 4 de sequentie-analyses uitgevoerd voor 24 nierweefsels uit 
ons ADPKD muismodel (Pkd1cko) in verschillende ziektestadia om de genen te bestuderen 
die betrokken zijn bij cystevorming en -progressie. We hebben de nieren op basis van de 
ernst van de ziekte in drie groepen ingedeeld; Vroege fase met nog bijna geen vorming van 
cysten, intermediaire fase met zichtbare cysten en eindfase met grote cysten die zich in de 
nieren vormen. We combineerden de gegevens van deze drie ziektefasen om te 
onderzoeken hoe veranderingen in genexpressie verband houden met de progressie van 
ADPKD, en kwam tot een reeks genen die betrokken zouden kunnen zijn bij de progressie 
van ADPKD, genaamd "ADPKD progressie profiel". Verder hebben we de chemo-
informatica-database (ChEMBL) gebruikt om te identificeren welke medicijnen kunnen 
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worden gebruikt om belangrijke genen in het “ADPKD progressie profiel” te targeten en zo de 
vorming van cysten en ziekteprogressie te vertragen of te stoppen. Dit werk nomineerde 
verschillende nieuwe kandidaat-geneesmiddelen om ADPKD te behandelen, zoals 
Birinapant en Gamma-linoleenzuur. In dit hoofdstuk hebben we specifiek gekeken naar 
geneesmiddelen die al in de klinische praktijk zijn goedgekeurd om andere ziekten te 
behandelen. Het onderzoeken van het gebruik van een medicijn dat voor een bepaalde 
ziekte wordt gebruikt voor een andere indicatie, is een opkomend gebied van 
medicijnontdekking, genaamd drug repurposing. Drug repurposing zou het ontwikkel- en 
toelatingstraject van medicijnen aanzienlijk kunnen versnellen. Er wordt gebruik gemaakt van 
onze klinische en toxicologische kennis van huidige medicijnen, waardoor ze gemakkelijker 
toe te passen zijn voor andere indicaties dan onbekende medicijnen. Daarnaast hebben we 
in dit hoofdstuk bio-informatica gecombineerd die zich bezighoudt met gegevens van genen 
en eiwitten, met chemo-informatica die zich bezighoudt met gegevens met betrekking tot 
kleine moleculen en medicijnen. 
Tenslotte richtte ik me in hoofdstuk 5 op de behoefte aan methoden die de enorme 
hoeveelheden biologische gegevens die dagelijks worden geproduceerd, kunnen 
combineren tot een zinvol formaat voor machines om wetenschappers te helpen nieuwe 
waardevolle relaties in de biologische wetenschappen te vinden. Kennis netwerken zijn een 
steeds populairder formaat om biologische gegevens op te slaan, waarbij gegevens uit 
verschillende biologische bronnen worden gecombineerd en geannoteerd tot betekenisvolle 
relaties die snel door machines kunnen worden doorzocht. Door al deze databronnen op één 
plek te hebben, kunnen wetenschappers verbanden leggen tussen verschillende vormen van 
data en komen veel biologische vragen aan de orde, zoals "welke medicijnen kunnen worden 
gebruikt om kanker te behandelen?", Of "welke genen veroorzaken diabetes?". In hoofdstuk-
5 van dit proefschrift hebben we onderzocht hoe we dergelijke kennis netwerken kunnen 
explorerenmet behulp van machine learning om te voorspellen welke biologische relaties 
“waar” en van hoge kwaliteit zouden kunnen zijn, zodat ze verder kunnen worden getest door 
wetenschappers in het laboratorium. Dergelijke methoden zijn erg belangrijk om biologische 
ontdekkingen te versnellen en fouten te minimaliseren. Het belang hiervan zal toenemen 
naarmate we doorgaan met het produceren van enorme hoeveelheden biologische 
gegevens die ons vermogen om te interpreteren en om te zetten in zinvolle biologische 




In the past 20 years the field of medical sciences witnessed significant achievements marked 
by the completion of the human genome project in 2003. From that moment, the costs of 
DNA sequencing dropped significantly. This marked the arrival of the data era in medical 
sciences. In this thesis, we focused on exploring the benefits of big data in treating human 
diseases, and specifically investigating novel treatments for Autosomal Dominant Polycystic 
Kidney Disease (ADPKD). ADPKD is a disease that impacts the patient’s kidneys, marked by 
liquid-filled cysts forming in both kidneys. ADPKD currently has very limited treatment options 
and could lead to patients developing end-stage renal disease and ultimately requiring 
kidney transplant.  
In chapter-2 of this thesis, we started by combining the different publicly available expression 
profiles of ADPKD, to arrive at a uniform ADPKD gene expression signature. Expression 
profiles are created by capturing the complete set of RNA transcripts (expressed genes) 
under specific circumstances or in a specific cell, using high-throughput sequencing analysis 
methods. Having a uniform expression signature enhances our understanding of the genes 
that are involved in the disease and minimizes errors that could come from using different 
technologies or different animal models when studying the disease. Single experiments are 
limited to a specific technology, animal model and/or disease state, there is value in 
combining different studies to overcome these limitations. In our work, we demonstrated that 
combining experiments across disease models and sequencing technologies creates a 
stronger gene signature with a higher chance of including genes that are modulated by the 
disease. Furthermore, in chapter-3, we used this expression signature to study a class of 
genes called transcription factors (TFs) and their role in ADPKD. Transcription factors are 
particularly interesting as they are capable of regulating the expression levels of other genes, 
making them key orchestrators of molecular events that could give rise to events such as 
cysts development in ADPKD patients. In chapter-3, we discovered two TFs, STAT3 and 
RUNX1 that could be further explored for their role in cysts formation. We also highlighted a 
few other genes that could be drug targeted by these two TFs to form a network of genes 
that act together to lead to significant molecular changes in ADPKD patients. In both 
chapters- 2 and 3, we relied on our ability to combine large amounts of transcriptomics data 
made possible by significant advancements in DNA sequencing technologies. 
Furthermore, in chapter-4, we sequenced 24 kidney tissues taken from our ADPKD mouse 
model (Pkd1cko) at different disease stages to study the genes implicated in cyst formation 
and progression. We grouped the kidneys based on their disease severity into three groups; 
Early-phase with almost no cysts formation yet, moderate-phase with visible cysts and, 
advanced-phase with large cysts formed in the kidneys. We combined the data from these 
three disease phases to explore how gene expression changes relate with the progression of 
ADPKD and were able to arrive at a set of genes that could be implicated in ADPKD 
progression called “ADPKD Progression Profile”.  Furthermore, we leveraged the 
chemoinformatics database (ChEMBL) to identify which drugs could be used to target 
important genes in the “ADPKD Progression Profile”, and hence slow down or stop cyst 
formation and disease progression. Combining bioinformatics  that is concerned with data 
from genes and protein with chemoinformatics that is concerned with data related to small 
molecules and drugs, enables a detailed analysis of which drugs could be used to target 
important proteins involved with ADPKD progress.This work nominated several novel drug 
candidates to treat ADPKD, such as Birinapant and Gamma-Linolenic acid. In this chapter, 
we looked specifically at drugs that are already approved in clinical practice to treat other 
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diseases. Exploring the use of a drug used for a certain disease for another indication is an 
emerging field of drug discovery called drug repurposing. Drug repurposing could 
significantly speed up drug development and market approval because it can leverage on 
existing clinical and toxicological knowledge.  
Finally, in chapter-5, we focused on addressing the need to have tools that can combine the 
vast amounts of biological data being produced on a daily basis into a meaningful format for 
machines to help scientists find new valuable relationships in biology. Knowledge graphs is 
an increasingly popular format to store biological data, where data combined from different 
biological sources, and annotated into meaningful relationships that could be quickly 
searched by machines. Having all these data sources in a single place, enables scientists to 
draw links between different forms of data and to address many biological questions such as 
“which drugs can be used to treat cancer?”, or “which genes cause diabetes?”. In chapter-5 
of this thesis, we studied how we could mine such knowledge graphs using machine learning 
to predict which biological relationships could be “true” and of high quality so that they could 
be further tested by scientists in the lab. Such methods are very important to speed-up 
biological discoveries and minimize errors. The importance of this kind of method will grow 
even further as we continue to produce vast amounts of biological data that outpaces our 
ability to interpret and convert into useful biological applications.  
In chapter-6, we offer a summary of the key findings of this thesis and discuss how they fit in 
the overall scientific picture of advancing molecular biology and disease study. We highlight 
that in addition to transcriptomics, scientists are increasingly exploring additional sources of 
data such as genomics and proteomics to study the flow of genetic information, and 
metabolomics and lipidomics to study the products of metabolism. Additionally, we shed light 
on several challenges that need to be tackled to unlock the full potential of these 
technologies in biomedical research, such as the need for automated methods to quickly 
connect data across different data formats and help scientists derive useful biological 
connections. To conclude, we are living in an exciting era, where biological advancements 
have the potential to revolutionize our way of living, not just in healthcare, but also in other 
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